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 Tuberculosis (TB) is a critical infectious disease world-wide, and the increasing 
development of antibiotic resistance drives the search for effective host-directed therapies. 
One molecular target of potential host-directed therapy is Type 1 Interferon, (IFN-I or 
IFNβ), an excess of which correlates with TB progression. The mechanisms underlying 
IFNβ overproduction are still unclear. In this dissertation we review cellular mechanisms, 
including mitochondrial function and metabolism, oxidative stress, and the Integrated 
Stress Response, which are involved in IFNβ production and macrophage function. We 
also describe an experimental model of human-like TB, the B6J.C3-Sst1C3HeB/Fej Krmn 
(B6.Sst1S) mouse, which provides a unique and convenient system for studying 
mechanisms of necrosis in TB granulomas. 
vii 
 We use primary macrophages from the B6.Sst1S mouse to establish a mechanism 
that links the B6.Sst1S genotype to a cascade of dysregulation that drives IFNβ 
superinduction and susceptibility to TB infection. TNF is necessary for granuloma 
formation in vivo, but in the context of transcriptional dysregulation and excess free iron, 
it drives oxidative stress, which amplifies IFNβ induction to pathologic levels. This 
induction is maintained by positive feedback through the double stranded RNA-dependent 
Protein Kinase (PKR). We demonstrate that interruption of this cascade by iron chelation 
or inhibition of lipid peroxidation attenuates IFNβ induction and improves subsequent 
infection outcomes. We conclude by comparing the in vitro model system to an in vivo 
necrotic TB granuloma, describing similarities between our system and human TB, and 
discussing the connections between IFN-I and autoimmune and degenerative disease and 
the broader application of the B6.Sst1S model system to studies of human immunity. 
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INTRODUCTION1 
Significance of Mycobacterium tuberculosis in human disease, and its impact on public 
health. 
Mycobacterium tuberculosis (M.tb) is the single most widespread pathogen in humans 
worldwide, with an estimated 1.7 billion people infected [1]. Despite the availability of 
multiple antibiotics to treat this pathogen, it is by no means controlled, with 1.5 million 
TB-related deaths recorded in 2018. The greatest burden of disease is in the developing 
world where the disease is endemic, treatment resources are scarce, and the emergence of 
drug-resistant strains as well as co-infection with HIV further complicate the treatment 
process and result in greatly increased mortality. M.tb is spread between human hosts by 
aerosol inhalation, typically between those living in close proximity [2]. Unlike other 
mycobacterial species, M.tb has no environmental reservoir, meaning it is only transmitted 
between human hosts [3]. 
 Tuberculosis, the disease caused by Mycobacterium tuberculosis infection, can be 
classified into three major patterns: primary, latent, and reactivation TB. Infection with 
M.tb is potentially serious, but most individuals exposed to the pathogen will never develop 
tuberculosis as a symptomatic disease. A majority develop a rapid immune response and 
clear the infection entirely when first exposed [4]. Approximately 5% of those who do not 
clear infection will develop Primary Active Tuberculosis, defined as symptomatic disease 
up to 18 months post-exposure [5]. Often, primary disease occurs in children and those 
                                                          
1 The section of this chapter titled “The Sst1S mouse model for susceptibility to tuberculosis” is part of a 
manuscript submitted for publication. This section was primarily written by me, with contributions from 
Igor Kramnik and Vadim Zhernovkov.  
2 
with immune deficiencies, either hereditary or acquired, such as HIV (human 
immunodeficiency virus). However, more than ninety percent of infected patients will not 
show primary disease, but will instead develop Latent tuberculosis [6]. In latent TB, low 
numbers of mycobacteria persist within a sequestered structure in the lungs called a 
granuloma [7] without causing disease symptoms. The granuloma structure is formed by 
the host immune system in response to the mycobacteria, and plays a critical role in the 
pathogenesis of the disease; it will be discussed in greater detail below. M.tb isolated within 
granulomas can persist in a latent state for years, decades, or the patient’s entire life. 
Approximately 10% of latent infections will progress to reactivated tuberculosis within the 
patient’s lifetime. In these cases, a triggering event or immune dysfunction causes a failure 
in the granuloma’s ability to contain the mycobacteria, which proliferate and escape into 
surrounding tissue, causing additional pulmonary lesions, or occasionally disseminated 
disease [8]. A fourth disease pattern of TB, disseminated disease or extra-pulmonary 
tuberculosis, is possible if an existing infection spreads through the blood or lymphatic 
system [9]. Although extrapulmonary TB is a serious and potentially deadly condition that 
can develop in nearly any tissue of the body, it is relatively uncommon compared to 
pulmonary TB. From an epidemiology perspective, extrapulmonary TB is ultimately a non-
productive infection, because it does not result in aerosolization and transmission of the 
mycobacterium. We will only be considering pulmonary TB disease in this thesis.  
 Classifying TB disease patterns allows for differential treatments that target 
different stages of the infection. In the United States, latent tuberculosis is typically treated 
with a combination of two antibiotics, isoniazid and rifampin or rifapentine for 3 months 
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[10]. However, active disease is more severe and must be treated with additional antibiotics 
(typically pyrazinamide and ethambutol) for a longer time period, up to 6 or 9 months, 
depending on the specific regimen [10]. In countries where TB is endemic, the differences 
in treatment between latent and active disease may be more stark [11], as endemic areas 
may have higher rates of drug resistant TB, which require even longer treatments with 
additional, side effect-prone therapies [12]. Furthermore, regular screenings may not be 
available in resource-limited settings to detect latent TB, and thus it may not be treated at 
all. This is problematic, because preemptive treatment of latent disease is more cost-
effective and has lower morbidity than reactive treatment of active disease. On the other 
hand, the majority of latent TB cases will never progress to active disease, so not all cases 
would ultimately require treatment, and treatment of every case of latent disease is simply 
not possible in endemic areas with limited healthcare resources. The ideal solution would 
be a low-cost method to determine which latent cases are at risk for progression to active 
disease, and preemptively treat those cases, making the most efficient use of resources. To 
make such predictions will require a better understanding of mycobacterial factors that 
affect the pathogen’s life cycle, as well as host factors that determine human susceptibility 
to tuberculosis. In this thesis we will use a mouse model system to elucidate host-pathogen 
interactions that determine host susceptibility to tuberculosis infection.  
Role of M. tuberculosis in inducing cell death and granuloma necrosis in susceptible 
hosts. 
 A hallmark of human tuberculosis is the development of a necrotic or “caseous” 
granuloma [7]. The tuberculous granuloma is a host-protective multilayer structure 
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composed of a variety of immune cells and fibrotic tissue, encapsulating the mycobacteria. 
A central necrotic region containing mycobacteria and cellular debris is surrounded by a 
region of blood-derived macrophages that form the first line of defense against M.tb 
infection. [13]. M.tb is an intracellular infection and survives in the phagosomes and 
cytoplasm of infected macrophages, so the innermost macrophages of the granuloma may 
also contain live mycobacteria and fuel the infection. Surrounding this inner layer, 
uninfected macrophages form a fibrous, epithelioid layer, which creates a physical barrier 
that contains infection. Outside of this fibrous macrophage layer is a supportive 
lymphocyte layer, containing primarily CD4+ T cells, with scattered CD8+ and B cells 
[14]. See Figure 1A for a schematic, or Figure 2A and D for example histology. These 
lymphocytes and macrophages balance the pro- and anti-inflammatory cytokines to 
maintain the granuloma without causing excess damage to the surrounding tissue. TNF 
from macrophages and IFNγ from CD4+ T cells balance against IL-10 from multiple 
sources  to regulate the immune function of the granuloma [15].  
 These cytokines, along with environmental factors and host genetics determine the 
integrity of the granuloma structure, and thus the mycobacterial success or failure. 
Moreover, host factors vary across the human population, resulting in the different disease 
patterns observed after infection with the same pathogen. The factors involved in host-
pathogen interaction play a role in the emergence and maintenance of necrotic 
granulomas[16, 17]. One such host factor is Type 1 Interferon (IFNβ), which has been 
observed at increased levels in the blood and pleural fluid of TB-infected patients [18]. The 
effects of IFNβ on outcomes of Tuberculosis have not been characterized as exclusively 
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positive or negative—while excess IFNβ appears to be detrimental to the host, eliminating 
the signal increases pathogenesis because it disrupts a complex cytokine system [19, 20]. 
Most of the research on IFNβ has focused on the downstream signaling consequences, and 
comparatively little is known about the upstream regulators in the context of M.tb infection. 
In this thesis we use a mouse model of IFNβ overproduction and TB susceptibility to 
describe cell intrinsic signals that affect IFNβ signaling, and contribute to the increased 
susceptibility to Mycobacterium tuberculosis infection.  
The B6.Sst1S mouse model for susceptibility to tuberculosis.  
 We use a murine model of TB susceptibility to study the dichotomy between hosts 
that develop resolving TB lesions and those that develop caseating lesions with necrotic 
centers. The B6J.C3-sst1C3HeB/FejKrmn (B6.Sst1S) mouse model differs from the parent 
C57Bl6/J (B6.WT) strain only at the “super-susceptibility to Tuberculosis” or sst1 gene 
locus [21]. This locus encodes the murine homologs to human Speckled Protein family 
members SP110 and SP140 which are expressed in B6.WT macrophages, but minimally 
expressed in B6.Sst1S macrophages. The function of these genes is not fully described in 
mice, but their domain structure indicates chromatin binding and their human homologs 
have been implicated in transcriptional regulation and possible heterchromatin 
enforcement [22, 23]. It is hypothesized that the transcriptional differences between the 
mouse strains underlie the different phenotypic responses to TB. Regardless of the 
mechanism, the variation in this gene locus is sufficient to disrupt cell-intrinsic signal 
regulation, resulting in drastically different infection outcomes. When B6.WT mice are 
infected with low counts of M.tb, to mimic conditions of natural transmission, the mice 
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develop predominantly solid fibrotic lesions, which are the remnants of infectious loci that 
resolved. However, B6.Sst1S mice, infected under the same conditions, develop human-
like necrotic granulomas, with a complete structure of a necrotic core surrounded by 
infected and supporting macrophages, and a periphery of supporting T-lymphocytes.  
We model this granuloma environment in vitro by isolating and maturing macrophages 
from bone marrow, then stimulating them with TNF, which a macrophage would encounter 
in vivo as it enters the periphery of the granuloma. TNF is one of the two major cytokines 
required for granuloma formation (the other being IFNγ) [24], and this simplified cytokine 
stimulation is sufficient to elicit differential strain-dependent responses [25]. Under these 
conditions, a major difference between B6.Sst1S and B6.WT is the regulation of Type 1 
IFN (IFN-I or IFNβ). B6.Sst1S macrophages display a “superinduction” of IFNβ starting 
8-12 hours after stimulation with TNF, far above the normal regulated induction seen in 
B6.WT [25]. Higher levels of type 1 IFN have also been associated in humans with active 
TB [19], and an excess of IFNβ production in TB infection is known to be maladaptive on 
the part of the host macrophage [26]. TNF activates IFNβ via the NFκB pathway, 
specifically the p50/RelA dimer. P50 and RelA are early activators of IFNβ transcription, 
and despite not producing high levels of IFNβ on their own, may be critical for initiation 
of IFNβ signaling in naive cells [27]. Once induced at low levels by NFkB, IFNβ is further 
superinduced through JNK’s action on transcription factor c-Jun, as previously described 
in B6.Sst1S [25].  
 Downstream of IFN-I, another major pathway differentiates the B6.Sst1S and 
B6.WT strains. Upon TNF stimulation, B6.Sst1S macrophages activate the Integrated 
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Stress Response (ISR), a regulatory mechanism that blocks cap-dependent translation in 
response to various cellular stresses. These stresses include amino acid starvation (GCN2, 
General aminoacid Control, Non-depressible 2), ER stress (PERK, PKR-like Endoplasmic 
Reticulum Kinase), Heme deprivation (HRI, Heme Responsive Inhibitor), and dsRNA 
recognition (PKR), and of these, PKR has been shown to play the most significant role in 
the B6.Sst1S system [25, 28]. The ISR is a homeostatic mechanism when activated 
appropriately, although a prolonged blockade of cap-dependent translation can cause 
additional problems, even leading to cell death. Moreover, B6.WT macrophages do not 
activate the ISR in response to TNF, suggesting that its activation in B6.Sst1S may be 
inappropriate, or is at best a compensatory mechanism for an unresolving, strain-specific 
stressor. Treatment with a small-molecule inhibitor ISR inhibitor (ISRIB) has been 
demonstrated to reduce inflammation and necrosis in the lungs of M.tb-infected B6.Sst1S 
mice [25], suggesting that ISR activation is detrimental. However, the underlying stressor 
that activates this pathway is thus far unclear, and may continue to drive pathology even 
with inhibition of the ISR itself.  
 Given the importance of Type 1 IFN and downstream pathways to infection 
outcomes, as well as the chronic course of Tuberculosis infection, we focused our studies 
on the mechanisms of IFNβ dysregulation in B6.Sst1S. Some consequences of IFNβ 
superinduction with regard to infection have already been explored, including the ISR as 
mentioned above, as well as a clear mechanistic link to susceptibility via IFNβ’s 
upregulation of IL-1 receptor antagonist [29]. However, addition of exogenous factors has 
been unable to fully rectify or recreate the B6.Sst1S susceptibility phenotype. Therefore, 
8 
we focused on cell-intrinsic factors related to IFNβ superinduction that promote 
susceptibility by driving cellular stress, dysfunction, and damage. Importantly, the 
B6.Sst1S macrophage model develops a damaging cascade of dysregulation upon TNF 
stimulation, even in the absence of M.tb infection. The susceptibility phenotype is a 
consequence of intrinsic macrophage dysfunction that impairs the cell’s ability to survive 
infection. We will therefore be analyzing and discussing mechanisms that are independent 
of M.tb, and then building a connection to tuberculosis by observing infection outcomes in 
the context of a dysregulated state. 
 Using this model, we attempt to address the following questions and knowledge 
gaps. First, IFNβ is superinduced in B6.Sst1S macrophages with TNF, but the mechanisms 
that initiate and maintain this superinduction are not well understood. We will first discuss 
known transcription factors that induce IFNβ and their associated signaling pathways, and 
then describe experimental results that indicate which of these pathways drive 
superinduction in B6.Sst1S. Second, we have observed PKR playing a role in B6.Sst1S in 
the absence of viral RNA, its canonical activator. We will therefore describe known non-
canonical activators of PKR, before examining experimental results that suggest a possible 
source for its activation. Third, we know that Reactive Oxygen Species (ROS) play an 
important role both in the B6.Sst1S system and in tuberculosis infection in healthy hosts. 
The principal source of ROS dysregulation in B6.Sst1S is not known, nor is the extent of 
ROS involvement in the B6.Sst1S phenotype, however a mitochondrial connection is likely 
due to certain observed metabolic anomalies. We will therefore explore potential sources 
and effects of ROS in the B6.Sst1S macrophage, and the roles of mitochondrial function 
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and dysfunction in macrophage function and cell death. Finally, we will experimentally 
connect these apparently disparate mechanics into the cascade of dysfunction in B6.Sst1S 
that leads to susceptibility to TB.  
Mechanisms of Type 1 Interferon induction in the host macrophage 
The IFNβ enhanceosome 
Type I interferons, IFN-I or IFNβ, play a major role in the progression of Tuberculosis 
infection, and in the B6.Sst1S model system in particular. IFNβ is highly regulated, and 
dysregulation at the transcriptional level in B6.Sst1S macrophages results in significant 
cellular dysfunction. Therefore, understanding the transcription factors involved in IFNβ 
induction is necessary for any discussion of IFNβ function. IFNβ is activated by a series of 
transcription factors that sequentially bind in a complex termed the IFNβ enhanceosome 
(Figure 1B). The major components of the enhanceosome are NFκB subunits p50 and 
RelA, IRF1, 3 and 7, ATF-2 and cJun. The structure of the enhanceosome allows multiple 
transcription factors to influence IFNβ induction simultaneously, which allows signals 
from multiple pathways to be integrated to produce a specific level of IFNβ [30]. For 
example, NFκB subunits alone may induce low levels of IFNβ, while NFκB, cJun and IRF3 
signaling together synergize to induce much higher levels than any individual factor alone. 
 Critical components of the enhanceosome include the interferon regulatory factor 
family of transcription factors which interact with the Interferon Beta promoter [31]. The 
first discovered family member, IRF1, is induced when IFNγ signals through IFGR1/2 to 
the Jak/Stat pathway [32], but has also been shown to induce IFNβ in a TLR9-MyD88-
IRF1-IFNβ sequence [33]. IRF1 binds and supports enhanceosome assembly [34], but 
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individually induces relatively low levels of IFNβ [31].  IRF3 and IRF7 are the strongest 
IRF family inducers of IFNβ expression, and respond to a variety of stimuli. IRF3 is 
activated either through a pathway of TLR 3 or 4 recruitment of adaptors TRIF/TRAM and 
signaling through TBK1, or by RIG-I/PS1 and TBK1/Iκκe [35]. IRF3 therefore responds 
to both viral dsRNA (RIG-I and TLR3) and bacterial LPS (TLR4), and produces a high 
level of IFNβ induction, even in the absence of other enhanceosome factors. IRF7 may also 
be essential for significant viral-induced IFN responses, as well as MyD88-dependent 
TLR-activated IFN responses [36]. IRF7 is activated downstream of RIG-I [35], as with 
IRF3, and is similarly phosphorylated, but can alternatively be activated by RIP1, via 
TRAF6 through the TNF receptor pathway [37]. Finally, IRF7 plays an important role in 
positive feedback, as it can be activated downstream of the IFN alpha receptor (IFNAR), 
and thus both promotes IFNβ induction and responds to exogenous or autocrine IFNβ 
signals [38]. Taken together, IRF3 and IRF7 produce the greatest effect on IFNβ activation 
of the enhanceosome elements. 
 Although the IRFs plays a critical role in IFNβ activation, other transcription 
factors assure optimal transcription control.  NFκB, specifically the p50/RelA dimer, is an 
important early contributor to IFNβ activation. LPS is recognized by TLR4, which signals 
through MyD88, TRAF6, IRAK, [35], dsRNA can activate PKR, and TNF can signal 
through the TNF receptor, which transduces the signal through TRADD/TRAF and TAK1 
[39], all of which converge on Iκκ, resulting in IκB degradation and NFκB activation. P50 
and RelA are early activators of IFNβ transcription, and despite not producing high levels 
of IFNβ on their own, may be critical for initiation of IFN signaling in naive cells producing 
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baseline IFNβ levels [40]. Other activators of NFκB include bacterial peptidoglycans such 
as iE-DAP (D-gamma-glutamyl-meso-DAP dipeptide) and muramyl dipeptide (MDP), 
which activate NOD 1 and 2 respectively which signals through RIP2 and NEMO to the 
Iκκ/NFκB system. RIP2 also signals through Tak1/TAB2/3 and JNK/ERK/p38 to C-
fos/Jun [41]. In some reports, NFκB activation and translocation to the nucleus has been 
shown to respond to reactive oxygen species (ROS) [42]. NFκB activation initiates pro-
inflammatory signaling in macrophages as they enter areas of infection and inflammation 
with bacterial products, inflammatory cytokines, and abundant ROS from activated innate 
immune cells.  
 C-Jun, another critical IFNβ inducer, is part of the AP-1 transcription factor 
complex, and is phosphorylated downstream of the MAPK pathway, specifically JNK and 
ERK, each of which respond to various cellular stimuli [43]. ATF2 binds along with c-Jun, 
is also part of the AP-1 transcription factor group, and similarly responds to a wide variety 
of stimuli, including growth factors, UV irradiation, cytokines, and other stressors, through 
stress-activated protein kinase p38 [44]. In our system, these factors are particularly 
relevant for the role they play in a novel feedback loop. As described in the below results, 
the IFNβ enhanceosome, once activated through factors such as NFκB, is further developed 
by the actions of PKR. PKR, induced by initial IFNβ signaling, and activated from viral or 
bacterial products [45], signals through MKK to JNK and p38, which in turn activate the 
transcription factors c-Jun and ATF-2 [46]. PKR can also signal through the NFκB system 
[47], or through STAT1/STAT3 to activate c-fos [48]. All of these transcription factors act 
to continue induction of IFNβ transcription to provide an escalating response.  
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PKR and the Integrated stress response are critical effectors downstream of Type I 
IFN  
 The Integrated Stress Response (ISR) is a stress-resolution mechanism that 
responds to a variety of signals by inhibiting cap-dependent translation. Four kinases 
initiate the pathway by phosphorylating the eukaryotic initiation factor eIF2α: Heme-
regulated eIF2α kinase (HRI), General control non-depressible protein 2 (GCN2), RNA-
dependent Protein Kinase (PKR), and PKR-like ER kinase (PERK) [28]. These kinases 
canonically respond to heme insufficiency, amino acid deprivation, double-stranded RNA, 
and ER stress respectively. The eIF2 complex initiates translation by escorting the f-Met 
initiator tRNA to the 40s ribosome, but the phosphorylation of eIF2α blocks the interaction 
with guanine nucleotide exchange factor that allows for eIF2 recycling [49]. This inhibition 
decreases global cap-dependent protein translation, but allows induction and continued 
translation of certain stress resolution proteins. The transcription factor ATF4 is the best-
characterized ISR effector, and its multiple levels of regulation and various transcription 
factor binding partners allow for a tailored response to the initiating stressor [28, 50]. While 
each ISR activator has critical and nuanced effects on the cell, PKR is the most relevant to 
the regulation of IFNβ and to ISR activation in the B6.Sst1S model. 
PKR activates JNK and NFκB in response to inflammatory stressors 
 Best known for its role as a viral RNA sensor, double-stranded RNA-dependent 
Protein Kinase (PKR) plays an important role in Type I Interferon function, and is 
especially relevant in the B6.Sst1S model of tuberculosis susceptibility. PKR functions as 
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a regulator of translation via the Integrated Stress Response, by phosphorylating eIF2α 
when activated. Blocking translation in this manner is thought to be beneficial in cells 
which would otherwise be producing viral proteins, or those with unresolved proteotoxic 
stress. In addition to this antiviral effect, PKR is also involved in TNF and JNK signaling 
[51]. In the absence of PKR, TNF-treated MEFs do not activate NFκB, JNK, or AKT, and 
do not undergo proliferation. TNF and JNK-dependent pathways lead to IFNβ induction, 
and their dependence on PKR indicates possible mechanisms for a feedback loop between 
PKR and IFNβ. 
 Several studies have shown that PKR is required for the activation of JNK and p38 
by multiple mechanisms, suggesting a close link between the two signaling molecules. In 
the absence of PKR, JNK and p38 are not phosphorylated after viral infection. This 
interaction subsequently contributes to IFNβ induction, and may involve IPS-1 (IFNβ 
promoting simulator) as an adapter protein [52]. Even in the absence of viral infection, 
PKR is still necessary for JNK activation by certain stimuli. Bacterial products that activate 
JNK, including LPS and poly-IC, also require PKR for this activation [53]. Besides viral 
and bacterial signals,  internal cellular stresses, including lipotoxic stress and ER stress, 
also signal through PKR to activate JNK [54]. PKR is also required for p38 activation, and 
in turn for activation of NFκB, Stat1, and ATF-2 pathways [53]. Mice lacking PKR 
expression are unable to activate NFκB in response to poly I:C [55]. However, these mice 
still activate NFκB upon TNF stimulation, suggesting that PKR is involved in bacterial 
endotoxin recognition. However, PKR is not universally required for the activation of JNK, 
as heat shock and arsenite treatment cause JNK activation in a non-PKR dependent manner 
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[53]. This suggests that PKR selectively signals in response to inflammation-associated 
stressors, but is not a universal stress response kinase. While PKR may not be required for 
all responses to inflammatory cytokines, it does contribute to IFNγ signaling, as MEFs 
lacking PKR display a diminished response to IFNγ due to an inability to signal through 
IκB, NFκB and IRF1 [56]. 
PKR’s mechanism of activation 
 The above interactions are all dependent on PKR’s dsRNA binding domain 
(dsRBD), but are not necessarily dependent on the presence of viral RNA. A variety of 
PKR activators interact with the dsRBD to activate PKR. [57] Activation of PKR requires 
dimerization and phosphorylation, which occur concurrently and may be co-reinforcing. 
Dimerization via the RBD removes the autoinhibition and allows for cis-
autophosphorylation. In the case of dsRNA activation, 30bp of dsRNA or highly structured 
ssRNA can engage two dsRBDs and allow for efficient activation [58]. This binding does 
not require a specific sequence, but is selective for RNA over DNA [59]. 
 There is nothing unique about the viral RNA that canonically activates PKR. RNA 
from other sources, as long as it forms the appropriate structures, also binds the RBD. RNA 
from intracellular bacteria can encounter PKR after the lytic phase exhibited by some 
bacteria, or by direct secretion, as in Listeria species [60, 61]. Endogenous dsRNAs have 
also been demonstrated to interact with PKR in the absence of infection. These dsRNAs 
can be non-coding nuclear RNAs or mitochondrial mRNAs [62]. The circular 
mitochondrial genome is bi-directionally transcribed, which allows for the formation of 
RNA dimers. In cases of mitochondrial membrane disruption, or failure of certain 
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regulatory mechanisms, mitochondrial dsRNA has been shown to activate antiviral 
responses through MDA-5 [63, 64]. However, this RNA can also activate PKR, which may 
allow PKR to respond to mitochondrial damage in the context of metabolic and oxidative 
stress. 
 Activating RNAs can also be single stranded, provided they can form regions of 
double-stranded structure. In fact, cellular mRNA encoding TNF contains a segment in its 
3’ UTR that can activate PKR in order to phosphorylate eIF2α and enhance its own splicing 
[65]. Small nucleolar RNAs (snoRNAs) have also been demonstrated to activate PKR 
under conditions of metabolic stress. During palmitic acid treatment, an increase of 
snoRNA was co-immunoprecipitated with PKR, and this phenomenon was not dependent 
on changes in levels or localization of the snoRNAs [66]. This increase was shown to have 
a direct effect on increasing PKR autophosphorylation in MEFs, thus linking snoRNAs 
with functional PKR activation under non-viral metabolic stress conditions.  While the 
mechanisms of PKR signal transmission from unspliced nuclear RNA to cytoplasmic 
eIF2α is not yet understood, it has been shown that PKR can translocate to the nucleus 
under certain conditions, which may play a role in this process [67]. Additionally, PKR has 
been shown to regulate protein synthesis during mitosis [59]. In this case, PKR binds to 
dsRNAs formed by inverted Alu repeats, which are exposed to cytoplasmic PKR after the 
breakdown of the nuclear envelope. This function was shown to be important for mitotic 
progression and cytokinesis.  Recent studies have also shown binding of PKR to Alu 
elements in Small Interspersed Nuclear Elements (SINEs) during interphase [62].  
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PKR activation by PACT  
 PKR can dimerize in the absence of dsRNA [68], and numerous studies have 
demonstrated the potential for other stimuli to activate PKR, including those related to 
oxidative stress [69], as well as growth receptors and cytokines [56]. Importantly, PKR is  
induced and activated in MEFs upon stimulation with TNF [51], suggesting a role in non-
antiviral immune responses. One non-RNA activator of PKR is the aptly named PKR 
Activator Protein (PACT) [45]. Upon induction of stress with arsenite or peroxide, PACT 
is phosphorylated, binds to PKR, and activates PKR to phosphorylate eIF2α [70].  PACT 
integrates these non-RNA-dependent stressors into PKR activation. A defective RNA-
binding motif (which is similar in homology, but does not bind dsRNA) in PACT is 
responsible for its interaction with and activation of PKR, and binds to the PKR kinase 
domain with low affinity [71]. Under normal conditions, PACT is bound to TAR RNA 
Binding Protein (TRBP) an inhibitor of PACT and PKR, but dissociates under arsenite 
treatment or serum starvation [72], releasing PACT to homodimerize and/or activate PKR 
[73].  
 Additional activators of PKR include 5’-triphosphate ssRNAs (in the presence of 
IFNβ) [74], and the small molecule Heparin [75]. The physiological implications of these 
mechanisms have not been fully evaluated, but their existence suggests that PKR may play 
a role in integrating a larger variety of intracellular signals than those currently known. 
The roles of Mitochondria in IFNβ signaling 
 Metabolism and Mitochondrial function play a significant role in immunity, 
including in Type 1 Interferon signaling pathways. Mitochondrial damage can induce Type 
17 
1 IFN through cytosolic sensors detecting leaked mitochondrial nucleic acids, either 
mtDNA [76] or mt-dsRNA [62, 63]. In either case, mitochondrial membranes must rupture 
or become permeable, which is occurs during pre-apoptotic events [77], but can also be 
caused by activation of the Mitochondrial permeability transition pore by Ca2+ or oxidative 
stress [78]. Mitochondrial DNA is less likely to leak into the cytoplasm due to its larger 
size, but if it does, it can be recognized by cytoplasmic sensor cGAS to activate the 
Stimulator of Interferon Genes (STING), which powerfully induces IFN-I via IRF3 [79]. 
Mitochondrial RNA tends to be smaller in size, is often double stranded [80] and is 
recognized by a variety of sensors, including RIG-I and RLRs, NOD2, PKR, and non RLR 
helicases such as the DDX protein family, all of which can induce Type 1 IFN [81].  
IFN-I induces downstream signals that can cause mitochondrial dysfunction. First, IFN-I 
induces Rsad2 (aka Viperin), which interacts with multiple mitochondrial proteins. Rsad2 
can interact with MAVS to activate the TRADD/TRAF pathway leading to NFκB 
activation and programmed cell death through TRAF2 or Fas [82]. Rsad2 also inhibits 
Mitochondrial trifunctional protein, which is involved in fatty acid beta-oxidation [83, 84]. 
Through this pathway, excess IFNβ might reduce mitochondrial efficiency in producing 
ATP and NADH, especially under stress conditions, as beta oxidation is involved in both 
of these processes. Rsad2 is also known to interact with the VAP-A/SNARE-mediated 
vesicle transport, which is mediates cholesterol trafficking to mitochondria [85, 86]. 
Therefore, excess IFNβ may eventually affect mitochondrial membrane composition, and 
therefore affect both ATP production efficiency and membrane stability and repair.  
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 Second, IFNβ may influence mitochondrial function via IRG-1 induction of 
Itaconate. Itaconate is a succinate analogue known to be produced by macrophages upon 
exposure to LPS, but is mechanistically driven by Type 1 IFNs via IRG-1 [87]. Itaconate 
inhibits bacterial metabolic enzymes isocitrate lyase and propionyl-CoA carboxylase, but 
also affects macrophage enzymes. It inhibits iNOS, succinate dehydrogenase, and fructose-
6-phosphate 2-kinase, thus blocking glycolysis and the TCA cycle, and reducing pro-
inflammatory macrophage activation [88]. As a secondary effect, itaconate increases fatty 
acid use as an energy substrate, and increases overall oxidative phosphorylation and 
damaging mitochondrial ROS production [89, 90]. Thus, itaconate production reduces 
mitochondrial and cytoplasmic energy production, and increases mitochondrial oxidative 
stress while reducing cytoplasmic ROS, overall sacrificing some macrophage function for 
a bacteriostatic effect. Unfortunately for macrophages in a TB granuloma, M. tuberculosis 
is known to produce an enzyme to catabolize itaconate and resist its effects [91], making it 
a net detriment to the infected cell.  
 Third, IFNβ may interact indirectly with the mitochondria via activation of the 
integrated stress response (ISR). Mitochondrial function depends on maintaining balance 
between proteins of mitochondrial origin and those of nuclear origin. The integrated stress 
response selectively inhibits cap-dependent translation on eukaryotic ribosomes, but does 
not affect mitochondrial ribosomes. Therefore, prolonged ISR activation may result in a 
deficit of nuclear proteins compared to mitochondrial proteins, resulting in electron 
transport inefficiency and activation of repair mechanisms. An imbalance caused by 
disruption of mitochondrial ribosomes or mitochondrial DNA activates the mitochondrial 
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unfolded protein response (mitoUPR), and ISR effectors CHOP, ATF4 and ATF5 can also 
activate the mitoUPR [92]. The mitoUPR normally allows mitochondria to adapt to stress 
and survive, as long as it is balanced against appropriate mitochondrial fusion and 
mitophagy to recycle severely impaired individual mitochondria. Interestingly, however, 
prolonged mtUPR activation has been shown to be detrimental to the cell as a whole, 
because it can counteract mitophagy signals and allow damaged and inefficient 
mitochondria to survive, accumulating additional ROS and leaking cellular DAMPs [93].  
Reactive Oxygen Species sources and effects in macrophages. 
 Mitochondria are a major source of ROS, as products of oxidative phosphorylation. 
O2
- is produced in response to high ratios of NADH/NAD+ [94], or by reverse electron 
transport by Complex I or Complex II during impaired electron transport, either due to loss 
of H+ gradient or Complex I or III inhibition [95]. Stoichiometric imbalance of electron 
transport complexes can similarly result in ROS production, and occurs with different 
transcription or translation rates between the nuclear-derived complexes and the 
mitochondrial-derived complexes [96]. ISR activation is one potential cause of such 
imbalance. ROS produced in the mitochondria primarily remain in the intermembrane 
space or the mitochondrial matrix, and can react with mitochondrial membrane lipids and 
proteins.   
 ROS buffering in the mitochondria is managed by superoxide dismutase, 
glutathione, thioredoxin and peroxidredoxin protein families [97-99]. Disruption of any of 
these pathways results in overproduction of mitochondrial ROS. Imbalanced oxidative 
states in mitochondria can result in a variety of pathogenic and inflammatory processes. 
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Peroxidized lipids in the mitochondrial membrane alter membrane fluidity and affect 
cristae morphology [100], and affect energy production by reacting with membrane 
proteins such as electron transport complexes [101]. Significant mitochondrial damage 
activates the NLRP3 inflammasome, which initiates pyroptotic cell death, damages 
mitochondria and reduces mitophagy [102]. If damage is not extensive enough to result in 
cell death, inflammatory markers including IL1β are produced [103], and the reduction in 
mitophagy can result in toxic aggregates like those in degenerative diseases such as 
Parkinson’s [104].  
 Macrophages also produce ROS during the “Respiratory Burst,” an increased 
consumption of O2 to produce superoxide. This is catalyzed by NADPH oxidase (a 
complex including NOX2), and supports the bactericidal activity of macrophages and other 
phagocytes [105]. ROS production by NADPH oxidase is also regulated by non-bacterial 
signals, including minimally oxidized low-density lipoprotein [106], suggesting that ROS 
play roles in other, non-antimicrobial signaling pathways. NOX2/NADPH oxidase 
produces O2
- and NADP+, which supports an increased glycolytic function during the 
respiratory burst, consistent with the increased glycolysis observed in activated 
macrophages [107]. Another major contributor to ROS production in macrophages is 
inducible nitric oxide synthase (iNOS). NO produced by iNOS can react with O2
- to 
produce peroxynitrite, which if produced transiently, induces oxidative protection through 
glucose-6-phosphate dehydrogenase stimulation and NADPH production [108]. However, 
if iNOS is chronically active, peroxynitrite and NADPH establish positive feedback 
through NADPH oxidase, producing increasing and damaging levels of superoxides [109]. 
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 For our studies described below, is important to note that TNF plays a major role 
in the induction of the oxidative enzymes including those of the respiratory burst. Both 
NADPH oxidase and iNOS are downstream of TNF and NFκB [110, 111], but NFκB 
elements also upregulate COX-2, a pro-inflammatory signal enzyme [112], and interacts 
with Keap1 to reduce activation of NRF2 which is broadly involved in the antioxidant arm 
of oxidative homeostasis [113]. 
Antioxidant defenses and the prevention of cell death 
 The production of some level of oxidative stress from the above sources is 
inevitable, and essential for macrophage function, so to avoid rapid, excessive oxidative 
damage, macrophages have developed certain antioxidant defenses. A central regulator of 
antioxidant programs is Nuclear Factor E2-Related Factor 2 (NRF2) [114].  Under normal 
conditions, NRF2 is constitutively expressed, with its activity being regulated by rates of 
protein degradation [115]. To maintain this regulation, NRF2 is bound and sequestered in 
the cytoplasm by Keap1, where it is degraded [116] . Under oxidative stress, Keap1 can be 
inactivated by several  pathways, though modification of cysteine residues on Keap1 and  
through interaction with regulator proteins including p62, PGAM5, and p21 [117]. 
Inactivation of Keap1 results in either dissociation of NRF2 or failure to bind newly 
synthesized NRF2, depending on the pathway, and in either case, the translocation of free 
NRF2 into the nucleus to activate transcription by binding the Antioxidant Response 
Element (ARE or Electrophile Response Element/EpRE)  [114, 118]. Critical genes 
regulated by this pathway include glutathione S-transferase (GST) and NAD(P)H:quinone 
oxidoreductase-1 (NQO1) [119], which are involved in the global antioxidant response. 
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Also induced are genes involved in iron metabolism, including Ferritin heavy and light 
chains (FTL/FTH1), Hemeoxygenase 1 (HMOX1), and Ferrocheletase (FECH), as well as 
genes involved in prevention of lipid peroxidation and ferroptosis, such as glutathione 
peroxidase 4, peroxiredoxins 1 and 6, and thioredoxin reductase [120].   
 In cells with dysregulated iron homeostasis and oxidative stress, free ferrous iron 
(Fe2+) can react with hydrogen peroxide to form hydroxyl or hydroperoxyl radicals, which 
react with cellular lipids to form lipid peroxyl radicals [120, 121]. Radicals propagate until 
quenched, and the result of lipid peroxyl radicals interacting with another lipid is one lipid 
peroxide and another lipid radical, which can then repeat the reaction. At this stage, GPX4 
truncates the reaction by converting the lipid peroxides into less reactive lipid alcohols 
[122], however, this does not occur if GPX4 is inhibited due to low levels of Glutathione 
(GSH), or in the presence of specific inhibitors [123]. The accumulation of lipid peroxides 
is the defining feature of a mechanism of cell death called Ferroptosis (Figure 1C). While 
the full mechanism beyond the accumulation of lipid peroxides has not yet been described, 
Ferroptosis is morphologically characterized by mitochondrial shrinkage and loss of 
mitochondrial cristae, and increased membrane density [124, 125]. Ferroptosis appears to 
be a unique mechanism of cell death, and is not characterized by apoptotic morphology 
like cell shrinkage, chromatin condensation, cytoskeletal dissolution or autophagic 
vacuoles, nor does it involve cytosolic swelling and membrane rupture, as in necrosis 
[126]. Nevertheless, it is a clear loss of cellular function, and is beginning to be explored 
in greater detail as its mechanisms are linked to a variety of disease pathologies [125].  
Cellular responses to Mitochondrial Damage and Dysfunction 
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 When mitochondria are damaged by processes such as those mentioned above, a 
number of responses allow the cell to cope. For minor ROS overproduction, thiols in 
mitochondrial proteins may act as antioxidants to buffer reactive species. A major reservoir 
of thiols is Adenine Nucleotide Translocase, although oxidation of this enzyme reduces the 
effective energy output of the mitochondria by reducing ATP/ADP exchange across the 
mitochondrial membranes [127]. More significant ROS-induced damage will  activate 
Parkin/PINK1-dependent mitophagy in order to recycle the damaged mitochondria [128]. 
However, as previously mentioned, this mitophagy may be inhibited by the mitoUPR, and 
is also downregulated by IFNAR-associated JAK/Stat1 signaling [129, 130]. MitoROS 
activation of MTORC1 can also lead to cellular senescence, via HDM2 phosphorylation 
and activation of p53 [131].  In proliferating cells, this results in replicative senescence and 
loss of cell cycle progression, but in terminally differentiated macrophages, it  promotes an 
anti-inflammatory macrophage phenotype [132]. This may be useful in the context of 
oxidative insult, but in the context of bacterial infection like tuberculosis, it is less likely to 
be an appropriate response.  
 Failing resolution by other mechanisms, mitochondria may respond to 
overwhelming stress by initiating cell death pathways. When this occurs through BAX and 
BAK signaling, the mitochondrial membrane becomes permeable to release cytochrome 
C, a potent activator of Caspase 3 [133]. Mitochondrial membrane pores are not selective 
for cytochrome C, and it has been shown that when normal packaging of mitochondrial 
DNA by TFAM is disrupted during pre-apoptotic signaling, mtDNA are found in the 
cytosol [134]. This should result in concurrent caspase activation and a prioritization of 
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anti-inflammatory apoptosis over inflammatory IFN production, because caspases also 
reduce cGAS and STING levels. However, if caspases are inhibited, as by ERK/MEK 
signaling, mtDNA can activate cGAS/STING to promote a strong Type 1 Interferon 
response, as discussed above [135]. In the presence of mitoROS, additional IFNβ signaling 
can induce RIPK1 and RIPK3 to assemble into the “Necrosome,” which carries out 
necroptosis, or programmed necrotic cell death [136]. A third option is a death mechanism 
termed “parthanatos”, in which PARP1 assembles NAD+ into Poly-adenyl Ribose (PAR) 
in response to damage by ROS or RNS. PAR normally activates repair mechanisms, but if 
the repair mechanisms fail to resolve the stress, then long branched PAR chains form. 
These branched chains signal mitochondrial depolarization and AIF (apoptosis-inducing 
factor) release and nuclear translocation, leading to DNA cleavage in another form of 
apoptosis-like cell death [137]. It is not clear which cell death pathways occur in 
dysregulated or TB-infected B6.Sst1S macrophages, only that the result is predominantly 
necrotic. However, this does not exclude apoptotic or adjacent signaling, as multiple cell 
death pathways may be initiated in damaged B6.Sst1S macrophages. 
Summary 
 Appropriate interpretation of the experiments described in this dissertation requires 
an understanding of the above topics. Experiments are performed using the B6.Sst1S and 
B6.WT mice, or primary macrophages derived from these mice. The B6.Sst1S strain is 
genetically identical to the B6.WT strain except for the loss of the sst1 gene locus. 
Phenotypically, B6.Sst1S mice develop necrotic granulomas upon infection with M.tb, 
while B6.WT mice do not, and upon stimulation with TNF, B6.Sst1S macrophages develop 
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much higher levels of IFNβ induction than B6.WT and activate the Integrated Stress 
Response, which B6.WT macrophages do not. TNF drives IFNβ induction in both strains, 
but in B6.Sst1S, JNK and PKR drive IFNβ superinduction. PKR also drives the ISR. No 
viral RNA is present in this system, so PKR is activated by a non-viral source; nuclear and 
mitochondrial sources of RNA are experimentally assessed for their roles in PKR 
activation. Assessing transcriptomic differences between B6.Sst1S and B6.WT 
macrophages reveals dysregulated oxidative processes in B6.Sst1S, including reduced iron 
sequestration and increased lipid peroxidation. Mitochondrial dysfunction is also observed 
in B6.Sst1S macrophages, with possible connections to PKR activation, ROS generation, 
and cell death. Ultimately the dysregulation seen in B6.Sst1S macrophages drives the 
susceptibility to tuberculosis observed in B6.Sst1S mice, and TB granuloma structure will 
be discussed further in the interpretation of these studies.  
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RATIONALE AND AIMS 
 The B6.Sst1S macrophage develops a cascade of dysregulation due to the effects 
of a single genetic locus resulting in an inappropriate response to TNF. This cascade of 
dysfunction, in the context of TB infection, promotes macrophage cell death, granuloma 
tissue necrosis, and decreased survival in the infected animal. The B6.Sst1S mouse 
phenotype of TB susceptibility mimics human TB disease in its development of caseous, 
necrotic pulmonary granulomas. It is therefore expected that improved understanding of 
the mechanisms that drive macrophage dysfunction, cell death, and tissue necrosis, may 
lead to a better understanding of human TB disease as well, and may contribute to the 
development of host-directed therapies in the future. In the following experiments we 
bridge the knowledge gap between the loss of the sst1 gene locus and the superinduction 
of IFNβ that results in susceptibility to TB infection. We address the specific questions of 
which processes sustain IFNβ superinduction, what transcriptional differences exist 
between B6.WT and B6.Sst1S macrophages, and what metabolic consequences of these 
transcriptional differences drive cellular dysfunction and death.  
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MATERIALS AND METHODS 
Reagents 
Recombinant mouse TNF was purchased from Peprotech. Recombinant mouse IL-3 was 
purchased from R&D. Mouse monoclonal antibody to mouse TNF (MAb; clone XT22), 
Isotype control and mouse monoclonal antibody to mouse IFNβ (Clone: MAR1-5A3) were 
purchased from Thermo scientific. SP600125 and C-16 purchased from Calbiochem. PKR 
inhibitor structural control (CAS # 852547-30-9) purchased from Santa Cruz 
Biotechnology. BHA obtained from Sigma. FBS for cell culture medium obtained from 
HyClone. Middlebrook 7H9 mycobacterial growth medium and 7H10 agar plates were 
made in house according to established protocols. 
Animals 
C57BL/6J and C3HeB/FeJ inbred mice were obtained from the Jackson Laboratory (Bar 
Harbor, Maine, USA). The B6.C3H-sst1(B6J.C3-sst1C3HeB/FejKrmn) congenic mice 
were created by transferring the sst1 susceptible allele from C3HeB/FeJ mouse strain on 
the B6.WT (C57BL/6J) genetic background using twelve backcrosses (referred to as 
B6.Sst1S in the text). All experiments were performed with the full knowledge and 
approval of the Standing Committee on Animals at Boston University in accordance with 
relevant guidelines and regulations. 
Tissue Inactivation, Processing, and Histopathologic Interpretation 
Tissue samples were fixed for 72 hours in 4% paraformaldehyde, at which time tissues 
were removed from the BSL-3 laboratory and stored in 1X PBS at 4°C until processed in 
a Leica PELORIS automated vacuum infiltration processor (Leica, Wetzlar, Germany), 
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followed by paraffin embedding with a Histocore Arcadia paraffin embedding machine 
(Leica).  Paraformaldehyde-fixed, paraffin-embedded blocks were sectioned to 5 μm, 
transferred to positively charged slides, deparaffinized in xylene, and dehydrated in graded 
ethanol. Tissues sections were stained with hematoxylin and eosin (H&E) for 
histopathology and a New Fuchsin Method to detect Acid-Fast Bacilli (Poly Scientific 
R&D Corp Catalog #K093-16OZ, Bay Shore, NY).  
Chromogenic Monoplex Immunohistochemistry 
A rabbit specific HRP/DAB detection kit was employed (Abcam catalog #ab64261, 
Cambridge, United Kingdom). In brief, slides were deparaffinized and rehydrated, 
endogenous peroxidases were blocked with hydrogen peroxidase, antigen retrieval was 
performed with a citrate buffer for 40 minutes at 90°C using a NxGen Decloaking chamber 
(Biocare Medical, Pacheco, California), non-specific binding was blocked using a kit 
protein block, the primary antibody was applied at a 1.200 dilution, which cross-reacts with 
mycobacterium species (Biocare Medical catalog#CP140A,C) and was incubated for 1 
hour at room temperature, followed by an anti-rabbit antibody, DAB chromogen, and 
hematoxylin counterstain. Uninfected mouse lung was examined in parallel under identical 
conditions with no immunolabeling observed serving as a negative control.  
BMDMs culture and Treatment 
Isolation of mouse bone marrow and culture of BMDMs were carried out as previously 
described [21]. TNF-activated macrophages were obtained by culture of cells for various 
times with recombinant mouse TNF (10 ng/ml). 
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BMDM were seeded in tissue culture plates. Cells were treated with TNF and incubated 
for 24hrs at 37°C with 5% CO2. The media were replaced with new media and the cells 
were either incubated with TNF (Re-stimulation) or without TNF for additional 24hrs at 
37°C with 5% CO2. PKR inhibitor (C-16) 2 μM final, ISR inhibitor (ISRIB) 10μm final, 
a-IFNAR and a-Isotype antibody (1:100) were added 24hrs of TNF treatment with the 
media replacement. 
Infection with M. tuberculosis 
For infection experiments, M. tuberculosis H37Rv was grown in 7H9 liquid media for three 
days, harvested, and diluted in media without antibiotics to the appropriate MOI. 100 μL 
of M. tuberculosis-containing media at appropriate MOIs were added to BMDMs grown 
in a 96-well plate format and pre-treated for 24 hours with TNF, if applicable. The plates 
were then centrifuged at 500g for 5 minutes and incubated for one hour at 37 o C. Cells 
were then treated with Amikacin at 200μg/μL for 45 minutes, to kill any extracellular 
bacteria. Cells were then washed and cultured with TNF and inhibitors as applicable in 
DMEM/F12 containing 10% FBS medium without antibiotics at 37 o C in 5% CO 2 for 
the period described in each experiment, with media change and replacement of TNF 
and/or inhibitors every 48h. MOI were confirmed by colony counting on 7H10 agar plates. 
All procedures involving live M. tuberculosis were completed in Biosafety Level 3 
containment, in compliance with regulations from the Environmental Health and Safety at 
the National Emerging Infectious Disease Laboratories, the Boston Public Health 
Commission, and the Center for Disease Control. 
Cytotoxicity and Mycobacterial growth assays 
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Isolated and treated BMDMs were stained with Hoechst or Propidium Iodide nuclear 
staining. Media was removed and the staining reagent was added to the cells at a 1:100 
dilution in PBS for 30 minutes, after which cells are washed with PBS and imaged directly 
using the Celigo microplate cytometer (Nexcelom). For viability tests in infected cells, 
macrophages were cultured in 96-well plates and infected with M.tb as described above. 
At harvest samples were treated with Live-or-Dye™ Fixable Viability Stain (Biotium) at 
a 1:1000 dilution in PBS/1% FBS for 30 minutes. After the stain, samples were gently 
washed to ensure no loss of dead cells from the plate, and fixed with 4% Paraformaldehyde 
for 30 minutes. The fixative was again washed and replaced with PBS, after which sample 
plates were decontaminated for removal from containment. Images and cell counts for both 
infected and uninfected cells were acquired using a Celigo microplate cytometer 
(Nexcelom). The intracellular bacterial load was determined by quantitative real time PCR 
(qPCR) using specific set of M.tb and M.bovis-BCG primer/probes with BCG spikes added 
as internal control (details of the method has described in Yabaji et al., submitted for 
publication). 
RNA Isolation and quantitative PCR 
Total RNA was isolated using the RNeasy Plus mini kit (Qiagen). cDNA synthesis was 
performed using the High-Capacity cDNA Reverse Transcription Kit (ThermoFisher), or 
was completed during one-step qPCR using SuperScript II Reverse Transcriptase 
(Invitrogen). Real-time PCR was performed with the GoTaq qPCR Mastermix (Promega) 
using the CFX-96 real-time PCR System (Bio-Rad). Oligonucleotide primers were 
designed using Primer 3 software (table 13) and specificity was confirmed by Primer 
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efficiency analysis and melting curve analysis. Thermal cycling parameters involved 40 
cycles under the following conditions: 95 °C for 2 mins, 95 °C for 15 s and 60 °C for 60 s. 
Each sample was set up in triplicate and normalized to 18S expression by the ddCt method. 
Western Blot Analysis 
SDS-PAGE was completed on 8% Acrylamide Bis-Tris gels, self-made according to 
standard protocols. Whole cell lysates were prepared using RIPA lysis buffer (Thermo 
Scientific) with added protease and phosphatase inhibitors. Gels were run with 50ug total 
protein per well, as determined by BCA assay, and transferred to PVDF membrane 
(Millipore). After blocking for 2 hours in blocking buffer (Li-Cor) or 5% skim milk in 
TBS-T buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.1% Tween20]. the 
membranes were incubated overnight with primary antibody at 4o C. Bands were detected 
by chemiluminescence (ECL) kit (Thermo Scientific) or by Li-Cor Odyssey for fluorescent 
antibodies. Loading control β-actin (1:2000, Sigma) was evaluated on the same membrane. 
PKR antibody (Santa Cruz) was used at a dilution of 1:200, and phospho- PKR (Thr 446) 
antibody (Santa Cruz) was used at a dilution of 1:150. Secondary antibodies used include 
fluorescent goat anti-mouse (1:20,000) and anti-rabbit (1:20,000) (Li-Cor), and HRP-
conjugated goat anti-mouse (1:8000) and anti-rabbit (1:8000). 
Seahorse Extracellular Flux Analysis 
BMDMs were plated on Seahorse-specific 96-well culture dishes (obtained from Agilent) 
at a density of 12,000 cells in 200uL of DMEM/F12. Culture conditions were as described 
above. Seahorse analysis was completed as per the standard Agilent Stress Test Protocol 
43 with standardized Oligomycin and Antimycin, and an FCCP concentration of 2uM.  
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NAD/NADH and Senescence Assays 
BMDMs were grown on flat-bottomed 96-well culture dishes (ThermoFisher) until 
confluent. For NAD/NADH measurement, we used the EnzyFluo NAD/NADH Assay Kit 
from BioAssay Systems, following the protocol and calculations according to the 
manufacturer’s directions. For Senescence-associated β-galactosidase analysis, we used 
the MarkerGene™ Fluorescent Cellular Senescence Microtiterplate Assay Kit, which 
quantifies senescent cells using a fluorescein substrate for β-galactosidase. 
Transmission Electron Microscopy 
Macrophages were placed in 1x PBS on ice for 5 minutes to loosen adhesion to cell plate, 
then scraped into solution. Cells were pelleted at 300g for 5 minutes at RT, then fixed in a 
solution of 4% PFA. Fixed cells were collected by centrifugation and resuspended in a low-
melting point agarose solution at 42oC, then pelleted and allowed to cool and solidify. 
Fixed cell pellets in agarose gel were then post-fixed with 1% osmium tetroxide in 0.15M 
cacodylate buffer, dehydrated in 50, 90 and 100% serial acetone, and embedded in epoxy 
resin. Semi-thin sections were cut at 2 mm with a glass knife, and stained with toluidine 
blue for light microscopic examination. After a suitable area was chosen, a diamond knife 
was used to cut ultrathin sections, about 72 nm, which were then mounted on 200-mesh 
cleaning copper grids and stained with 4% uranyl acetate and 0.4% lead citrate. The 
sections were examined in a JEOL JEM-1010 transmission electron microscope and 
different magnification images were obtained with an Erlangshen ES100W digital camera 
(Gatan, Pleasanton, CA). 
Assay for Transposase Accessible Chromatin with Sequencing 
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The assay for transposase accessible chromatin with sequencing (ATAC-Seq) was 
performed on isolated and treated BMDMs using the methods described in Buenrostro et 
al 2015 [138]. Minor variations to this method included use of approximately 100,000 
macrophages by hemocytometer estimation, and titration of transposase reagent for 
optimal integration. Sequencing was performed by the Boston University Microarray and 
Sequencing Core. Preliminary analysis was completed using the Database for Annotation, 
Visualization, and Integrated Discovery, Laboratory of Human Retrovirology and 
Immunoinformatics [139, 140]. 
LPS-induced shock 
B6.WT, B6.Sst1S, and C3HeB/FeJ mice were injected intraperitoneally with 2.5, 5, 10 or 
20mg/kg LPS. For five days including the day of infection, mice were monitored three 
times daily, with daily weights and maximum health score recorded each day. Health scores 
were recorded from 0 to 9, with 0 indicating no distress and a score of 9 indicating the most 
severe distress. A score of 9 in two consecutive checks was considered indication for 
compassionate euthanasia according to the IACUC protocol. Scores were calculated as a 
composite of three sub-scores, each graded from 0 to 3, of activity, posture, and respiration. 
After 5 days, mice were monitored once daily for an additional 3 days to monitor for any 
further complications in recovery.   
34 
MACROPHAGE INTOLERANCE TO OXIDATIVE STRESS DRIVES TB 
PROGRESSION VIA TYPE I IFN HYPERACTIVITY IN A MODEL OF 
NECROTIC TB GRANULOMAS2 
RESULTS 
Enhanced susceptibility to necrotizing TB granulomas in B6.Sst1S mutants linked to 
decreased macrophage resilience to chronic stimulation with TNF  
 After aerosol infection with 25 - 50 CFU of virulent M.tb H37Rv, the B6.Sst1S 
mice develop heterogeneous pulmonary lesions. Necrotic pulmonary lesions are typically 
observed during the third month of infection. As demonstrated in Fig.2A., multiple areas 
of focal granulomatous bronchopneumonia, resembling solid TB lesions in the parental 
sst1-resistant, B6.WT mice (Fig. 2C), coexist with large, well-organized, caseating 
necrotic granulomas (Fig.2D). Importantly, no necrotizing granulomas are observed in 
other organs [141]. In contrast to reports that described TB progression in the sst1-
susceptible parental C3HeB/FeJ mice, the B6.Sst1S TB lesions are more heterogeneous, 
and are not uniformly necrotic. At this stage, we observed necrotizing pneumonia in less 
than 10% of the animals (Fig.2B and E). The development of necrotic pulmonary 
granulomas in the presence of lesions typical for immunocompetent, resistant hosts (B6), 
                                                          
2 The work in the Results and Discussion sections of this chapter has been submitted for publication. 
Coauthors include: Shivraj Yabaji, Vadim Zhernovkov, Kerstin Seidel, Bidisha Bhattacharya, Nicholas 
Crossland, Hui Chen, William Bishai, Boris Kholodenko, Alexander Gimelbrant, Lester Kobzik and Igor 
Kramnik. My contribution was devising the hypothesis, performing experiments, analyzing and interpreting 
the data and writing the manuscript. Shivraj Yabaji performed experiments shown in Fig 2G, 3, 9E, F and 
10. Vadim Zhernovkov performed experiments and designed graphics for Figure 8. Kerstin Seidel performed 
experiments for Figures 5A, 5B, 6A and 6B. Bidisha Bhattacharya performed experiments for Figures 2F, 
9B. Nicholas Crossland performed experiments for Figure 2 A-E. Hui Chen performed EM imaging shown 
in Figure 11C. Igor Kramnik helped devise the experimental plan, and assisted with the manuscript writing. 
Other co-authors contributed to the experimental plans and interpretation.  
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in combination with the chronic course of the disease, clearly demonstrate that the sst1S-
mediated necrotization of pulmonary TB lesions is not due to systemic failure of an 
essential host resistance mechanism. Because the sst1-mediated intra-granulomatous 
necrosis occurs in a lesion-specific manner, it is more likely driven by local factors, leading 
to a gradual deterioration of the granuloma’s cellular constituents. 
 TNF plays major roles in granuloma formation and maintenance both in human TB 
and in animal models [142]. It is produced by myeloid cells and M.tb-specific T cells within 
TB granulomas.  We have previously demonstrated that the B6.Sst1S macrophages develop 
an aberrant response to TNF in vitro within 12 - 18 h of TNF stimulation. This is 
characterized by upregulation of stress markers, but no cell death [25].  To determine 
whether prolonged TNF stimulation (as likely present in the face of persistent 
mycobacterial infection) would be sufficient to induce death of the sst1-susceptible 
macrophages, we stimulated bone marrow-derived macrophages (BMDMs) isolated from 
the B6.WT and B6.Sst1S mice with increasing concentrations of TNF for 24 – 48 h. We 
observed that 50 or 100 ng/mL TNF induces a moderate increase in cell death in B6.Sst1S, 
while B6.WT macrophages remain resilient (Fig.2F). Next we tested whether this modest 
increase in cell death can be prevented by standard apoptosis or necroptosis inhibitors - 
pan-caspase inhibitor z-VAD and Nec-1, respectively. Neither of the inhibitors reduced the 
percentage of dead cells in TNF-treated B6.Sst1S BMDMs, nor eliminated the difference 
in cell death between TNF-stimulated B6.WT and B6.Sst1S BMDMs (Fig.3). Thus, 
increased death in the B6.Sst1S did not amount to the rapid and massive cell death induced 
by TNF in the presence of protein translation inhibitor cycloheximide, as in a necroptosis 
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model [143], nor was it mediated by caspase activation. We postulated that the sst1-
mediated phenotype reflects chronic un-resolving stress which only modestly increases the 
probability of cell death per se, but which decreases the B6.Sst1S macrophage resilience 
to pathogen-induced stress, and impairs mycobacterial control. To test this hypothesis, we 
observed survival and death rates of B6.Sst1S macrophages, as well as M.tb growth rates, 
after 3 days with and without TNF stimulation. We observed reduced cell counts, increased 
death rates, and increased M.tb growth in B6.Sst1S macrophages under TNF-induced stress 
(Fig.2G).  We also compared the macrophage death between B6.Sst1S and B6.WT 
macrophages during a chronic infection course at low MOI (< 0.1). Use of low MOI 
allowed monitoring of the cells for longer periods, and is expected to better model chronic 
disease in vivo. Treatment with 10 ng/mL TNF resulted in increased cell death of the 
B6.Sst1S BMDMs by day 8 of infection (Fig.4). Thus, in this in vitro model of M.tb 
infection, the discrimination between the B6.WT and B6.Sst1S phenotypes required 
chronic infection with virulent M.tb and prolonged exposure to TNF. These observations 
are consistent with a postulate that the susceptible macrophage phenotype gradually 
emerges as a result of an aberrant response to a combination of chronic inflammatory 
stimuli and bacterial infection. 
Unresolving stress underlies the aberrant response of the B6.Sst1S macrophages to 
TNF  
Dominant role of persistent TNF stimulation in the escalating IFN-I response.  
To determine the mechanisms of chronic, TNF-induced cell dysfunction in B6.Sst1S 
macrophages, we initially focused on the IFN-I pathway, which is upregulated in B6.Sst1S 
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BMDMs and instrumental in escalation of the ISR at early time points after TNF 
stimulation [25]. We wanted to determine whether the B6.Sst1S macrophages were more 
sensitive than B6.WT to chronic TNF stimulation in terms of the type I IFN pathway 
upregulation as well. To exclude effects of other soluble mediators produced by TNF-
stimulated macrophages, we pre-stimulated BMDMs with TNF for 24 h, washed, replaced 
the medium, and either re-stimulated them with the same dose of TNF or left untreated 
(Fig.5A). This experimental design allowed us to compare effects of the sst1 locus on 
primary and secondary macrophage responses to TNF (Fig.5A, samples 1,2 and 3,4, 
respectively), as well as residual levels of transcripts that were maintained after the first 24 
h TNF treatment in the absence of the second TNF stimulation (5,6). 
 In agreement with our previous studies, after the first 24h TNF stimulation, we 
observed significantly higher upregulation of IFNβ and several inflammatory genes, 
including known targets of IFN-I in B6.Sst1S BMDMs, as compared to the B6.WT 
(Fig.5A, samples 1 and 2). The expression of IFNβ and Rsad2 mRNAs in the B6.WT 
macrophages were refractory to the second TNF stimulation, as both IFNβ and Rsad2 
levels returned to baseline at 48h either in the presence of in the absence of TNF (Fig.5A, 
samples 3 and 5, respectively). In contrast, the B6.Sst1S macrophages (i) responded to the 
second TNF stimulation and (ii) expressed elevated IFNβ mRNA levels even in the absence 
of TNF re-stimulation (samples 4 and 6, respectively). Interestingly the level of IFNβ 
expression in the non-restimulated B6.Sst1S macrophages was maintained at a similar level 
to that seen in B6.WT after primary stimulation with TNF for 24 h (samples 6 and 3, 
respectively). Similar expression patterns were observed for a well-known IFN-I 
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responsive gene, Rsad2. Distinct patterns of expression were observed for iNOS and 
IL1Ra, whose upregulation is also mediated by sst1. These genes responded to the second 
round of TNF stimulation in both B6.WT and B6.Sst1S macrophages (samples 3 vs 5 and 
4 vs 6, respectively). However, their expression levels in B6.WT after TNF re-stimulation 
(at 48 h) were similar to those of the B6.Sst1S macrophages without re-stimulation 
(samples 3 and 6, respectively).  These findings suggest that the B6.Sst1S macrophages 
either lack feedback mechanisms of transcriptional regulation for IFNβ and IFN-regulated 
genes, or activate additional feed-forward circuits that maintain the IFN-I pathway 
upregulation. 
 The critical role of TNF was demonstrated by administering a TNF-blocking 
antibody at 12 or at 24 hours after stimulation with TNF. This intervention results in 
reduction of IFNβ transcript levels to near-baseline at 36 hours (Fig. 5C, right panel). The 
findings contrast with results obtained using a similar experimental design to establish the 
extent to which this B6.Sst1S-specific phenotype was dependent on IFNβ signaling 
through IFNAR, a known feed-forward circuit in the IFN-I system. We added anti-IFNAR 
antibody along with the media change at 24 hours, to block further signaling through 
IFNAR after this point. The IFNAR1 blockade partially reduced the secondary TNF 
responses (Fig.5B, left panel). However, its effect was incomplete, especially in the case 
of IFNβ and iNOS transcripts. In addition, the residual expression of IFNβ, iNOS and 
IL1Ra (which are observed in TNF pre-stimulated B6.Sst1S BMDMs in the absence of 
TNF re-stimulation) was unaffected by the IFNAR blockade (Fig.5B, right panel). Hence, 
persistent TNF, but not IFN-I, signaling is necessary for sustaining the IFN-I pathway 
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upregulation in B6.Sst1S macrophages at 24 – 36 h, as well as during the earlier 12 – 24 h 
period of TNF stimulation (Fig.5C, left panel). These data implicated the sst1 locus in 
feedback regulation of TNF responses upstream of the IFN-I pathway escalation. 
JNK and PKR activation downstream from TNF sustain the IFN-I hyperactivity. 
Previously, we determined that the initial superinduction of IFNβ from 12 – 16 h of TNF 
stimulation was due to synergistic effects of NF- B- and JNK-mediated pathways. Next, 
we wanted to explore pathways involved in sustaining the elevated IFNβ expression in 
B6.Sst1S macrophages downstream of TNF signaling.  We extended our previous findings 
by demonstrating that the JNK inhibitor SP600125, added 18 hours after TNF was effective 
at inhibiting IFNβ levels by 24 hours (Fig.5D). This inhibitor was also efficient when added 
during the 30 – 34 h interval (Fig.6). Thus, this stress-activated kinase plays a central role 
both in promoting the IFNβ superinduction within 8 – 16 h of TNF stimulation, as well as 
in sustaining the IFNβ upregulation at later time points in TNF-stimulated B6.Sst1S 
macrophages.  
 Our observations of elevated IFNβ expression in TNF-primed B6.Sst1S 
macrophages even after TNF withdrawal (Fig.5A) prompted us to search for additional 
mechanisms involved in sustaining the IFNβ upregulation in the susceptible macrophages.  
We hypothesized that an unresolving integrated stress response (ISR) may drive JNK 
activation at later stages, because prolonged translation inhibition is known to induce 
ribotoxic stress and JNK activation [144]. However, a universal ISR inhibitor ISRIB that 
efficiently blocks ISR in our model [25], had no effect on the IFNβ expression during the 
24 – 36 period.  The PKR inhibitor 2-aminopurine did suppress the IFNβ induction by TNF 
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during this interval (Fig.5D).  We confirmed this unexpected result using another PKR 
inhibitor, C16. The PKR specificity of the C16 effect on the IFNβ upregulation was 
confirmed using an inactive structural control (Fig. 5E). This observation was especially 
puzzling because no role for PKR in IFNβ induction was shown at an earlier step of the 
IFNβ superinduction, between 12 and 16 hours in our previous studies [25].  
To explore this apparent contradiction, we studied the effects of PKR inhibition 
with C16 on IFNβ expression at various stages of TNF stimulation more precisely: the 
inhibitor was added at 6, 12, 18 and 24 h after TNF stimulation and RNA samples were 
collected 6 hrs after each treatment (Fig.5F diagram). We confirmed that PKR inhibition 
had no effect on IFNβ upregulation at the initial 6 - 12 h interval but observed partial 
inhibition at 12 - 18 hours and near-complete suppression at 24 and 30 hours (Fig.5F). We 
confirmed PKR upregulation and activation in TNF-stimulated B6.Sst1S BMDMs during 
this period using Western blot with total and activated (Thr 446 Phospho-PKR) PKR-
specific antibodies (Fig.5G). Thus, the PKR contribution to IFNβ upregulation gradually 
increased after 18 h of TNF stimulation. However, this effect could not be explained by a 
PKR-mediated ISR. However, alternative targets of activated PKR are known, including 
apoptosis stimulating kinase ASK1 (MAP3K5), which is upstream of JNK1 [145].  Thus, 
the increased role of PKR in IFNβ maintenance, perhaps by engaging additional targets, 
signifies transition from the early “super-induction” (12 – 18 h) to a later “maintenance” 
(24 -48h) stage of the B6.Sst1S TNF response. Theoretically this transition permits the 
formation of a self-sustained feedforward loop, such as JNK > IFNβ > PKR > JNK, 
maintaining and potentially amplifying the aberrant TNF response. 
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PKR limits the ISR escalation caused by prolonged TNF stimulation. 
In our previous experiments, we observed rapid upregulation of the ISR markers 
Trb3 and Chac1 in B6.Sst1S BMDMs between 12 and 16 h of TNF stimulation. Their 
abrupt induction was mediated by IFN-I, PKR and ISR signaling [25]. To monitor the ISR 
status during the “maintenance” phase, we examined the Trb3 and Chac1 mRNA 
expression during 24 – 48 h of TNF stimulation. The Trib3 and Chac1 mRNAs were highly 
expressed in TNF stimulated B6.Sst1S BMDMs at 24 hours, but not at all in B6.WT 
(Fig.7A, samples 1 and 2). Next, we compared the mRNA levels in cells that were either 
re-stimulated with TNF for an additional 24 h after the initial TNF treatment, or not re-
stimulated (as depicted in diagram in Fig.5A). The B6.WT cells showed no upregulation 
of the ISR genes after TNF re-stimulation (samples 3 and 5). In contrast, the ISR 
upregulation was sustained in the B6.Sst1S macrophages to 48 hours with or without TNF 
re-stimulation (Fig. 7A, samples 4 and 6). Their levels, however, were higher in the 
presence of TNF. This upregulation was partially dependent on IFNAR signaling (Fig.7B, 
left panel) and required persistent TNF signaling, because TNF blockade 12 hours before 
harvest significantly reduced Trib3 levels at 24 and 36 hours (Fig. 7C). The elevated 
expression of the ISR markers in the absence of TNF re-stimulation were maintained in the 
presence of IFNAR blocking antibodies. Thus, the residual ISR level was independent of 
TNF and IFN-I, resembling an expression pattern of IFNβ (Fig.5B). We hypothesized that 
PKR activity may be involved in the ISR maintenance, as well. 
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 Unexpectedly, PKR inhibition using C16 during the 24 – 48 h of TNF re-
stimulation led to dramatic upregulation of Trb3 and Chac1 mRNA expression (Fig.7D), 
contrasting the IFNβ downregulation by the same treatment (Fig.8, Fig.5D). This 
observation suggested to us that at this stage the ISR and IFNβ regulation were uncoupled. 
To determine whether other pathways may be involved in the ISR increase in addition to 
PKR at this advanced stage of TNF response, we compared isolated and combined effects 
of C16 and ISRIB on ISR marker upregulation during the 24-48 h period. Unlike PKR 
inhibitor C16, ISRIB completely inhibited the TNF-induced ISR. Moreover, when 
combining C16 and ISRIB, we observed that ISRIB efficiently suppressed the C16-induced 
ISR escalation as well (Fig.7D, lower panels). Next, we treated TNF-stimulated B6.Sst1S 
BMDMs with C16 for 6 and 16 hours (Fig.7E and 7F, respectively) prior to harvest at 24 
hours of TNF treatment. A 6-hour treatment with C16 (added at 18 hours) drastically 
reduces the initial Trib3 mRNA induction, on a level comparable with global ISR inhibition 
by ISRIB (Fig.7E). However, a longer C16 treatment of 16 hours (8 - 24 h of TNF 
stimulation) instead increased the ISR stress, as evidenced by significant upregulation of 
Trib3 mRNA (Fig.7F). 
 These observations suggested that during prolonged exposure to TNF and PKR 
blockade additional ISR pathways became activated. We reasoned that the IFNβ > PKR > 
ISR axis must be activated in response to an ongoing stressor in TNF-stimulated B6.Sst1S 
macrophages that emerges prior to PKR activation, i.e. within the first 8 – 16 h of TNF 
stimulation. In this scenario, PKR activation plays an adaptive role by reducing the cap-
dependent protein biosynthesis via eIF2α phosphorylation. Blocking PKR without 
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resolving the underlying stressor, however, results in the activation of alternative ISR 
pathways by other eIF2α kinases, such as PERK and HRI that are activated by misfolded 
proteins in ER and cytoplasm, respectively [28]. Previously we observed the upregulation 
of heat shock protein genes Hspa1a and Hspa1b specifically in the B6.Sst1S BMDMs, as 
early as 12 h of TNF stimulation, followed by the accumulation of protein aggregates and 
dramatic upregulation of Hsp1 protein within 24 – 48 h of TNF stimulation [25].  Taken 
together, these data suggest that protein misfolding and unresolved proteotoxic stress 
underlie the progression of the aberrant macrophage activation by TNF. 
Defective antioxidant response and free iron drives the escalation of the IFNβ and 
Stress Responses 
Transcriptomic analysis of B6.Sst1S and B6.WT macrophages.  
 To start revealing the deficiency that underlies the B6.Sst1S phenotype, we 
compared global mRNA expression profiles of B6.Sst1S and B6.WT macrophages at 12 
hours of TNF treatment using RNA-seq (Fig.9A). First, this analysis confirmed that the 
B6.Sst1S BMDMs displayed severely reduced expression of two candidate genes encoded 
within the sst1 locus: Sp110 and Sp140. These genes were strongly upregulated by TNF 
stimulation exclusively in the B6.WT macrophages. Second, at this time point we did not 
observe differential expression of ISR or IFN-I pathway genes between the B6.Sst1S and 
B6.WT cells, but we noted significant differences in genes involved in redox control 
(Fig.9A, right panel). Gene set enrichment analysis (GSEA) of genes differentially 
expressed between TNF-stimulated B6.Sst1S and B6.WT at that critical junction revealed 
that the mutant macrophages were deficient in detoxification of reactive oxygen species, 
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cholesterol homeostasis, fatty acid metabolism and oxidative phosphorylation, while 
sumoylation and DNA repair related pathways were upregulated (Table 2).  Next, we 
inferred mouse macrophage gene regulatory network using GENIE3 algorithm [146] and 
external gene expression data for mice macrophages derived from Gene Expression 
Omnibus (GEO) [147]. This network represents co-expression dependencies between 
transcription factors and their potential target genes, calculated based on mutual variation 
in expression level of gene pairs [148, 149]. This network analysis revealed that Sp110 and 
Sp140 genes co-express with Nfe2l1 (Nuclear Factor Erythroid 2 Like 1, also known as 
Nrf1) and Mtf (metal-responsive transcription factor) TFs in mouse macrophages (Fig. 9A, 
left panel). Therefore, we postulated that the sst1-encoded Sp110 and/or Sp140 may be 
involved in activation of the Nfe2l1- and Mtf1-mediated pathways. These TFs are involved 
in regulating the response to oxidative damage. Both GSEA and network analyses 
highlighted the potential differences in regulatory mechanism in response to oxidative 
stress in B6.Sst1S and B6.WT macrophages.  
 To test this hypothesis, we analyzed the expression of a gene ontology set “response 
to oxidative stress” (GO0006979, 416 genes, Fig.9b). We observed clear separation of 
these genes in two sst1-dependent clusters. Many known antioxidant genes were 
upregulated in TNF-stimulated B6.WT macrophages to a significantly higher degree as 
compared to the B6.Sst1S mutants. Functional pathway profiling revealed that the B6-
specific cluster represents genes involved in “detoxification of reactive oxygen species”, 
“Ferroptosis", “HIF-1” and “peroxisome” signaling pathways, while B6.Sst1S-specific 
cluster contains genes from “MyD88-independent TLR4”, “DNA repair”, “Oxidative 
45 
Stress Induced Senescence” and “SUMOylation” pathways (Table 3). Transcription factor 
binding site analysis of genes from the B6-specific cluster revealed an enrichment of 
Nfe2l2 binding site sequence motifs, while overrepresentation of E2F, Egr1 and Pbx3 
transcription factor binding sites was found for genes from B6.Sst1S-specific cluster 
(Table 4). A master regulator analysis also revealed a key role for Nfe2 TFs as key 
regulators of genes differentially induced by TNF in B6.WT and B6.Sst1S BMDMs (Table 
5). Both Nfe2l1 and Nfe2l2 transcripts were significantly upregulated in TNF-stimulated 
macrophages (Fig. 9A, right panel). The Nfe2l1 and Nfe2l2 TF are known to bind to 
promoters of an overlapping, but not identical, set of genes that contain anti-oxidant 
response elements (ARE) in their promoters [150]. However, in the B6.WT phenotype 
Nfe2l1 was upregulated to a greater extent, as compared to Nfe2l2, while a reverse 
relationship was observed in the mutant. This difference may explain preferential 
utilization of the Nfe2l TFs in B6.WT and B6.Sst1S. Thus, macrophages in the B6.WT and 
B6.Sst1S backgrounds respond to ROS by upregulation of different sets of genes: the 
superior B6.WT response to TNF-induced oxidative stress may be driven by preferential 
utilization of the Nfe2l1- and Mtf-mediated pathways.  
Antioxidant blockade and iron chelation correct the aberrant macrophage activation. 
 Because oxidative damage is a well-established inducer of JNK, we hypothesized 
that the JNK-mediated hyperactivation of the IFN-I and ISR was driven by oxidative stress. 
We then used the compound Butylated Hydroxyanisole (BHA), which is commonly used 
for its anti-oxidant function due to its activation of anti-oxidant response genes via AP-1 
[151], as a pre-treatment to TNF stimulation in B6.Sst1S macrophages, to allow time for 
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the cells to develop oxidative protection. We observed that IFNβ and Trib3 transcript levels 
were reduced to almost completely normal with BHA pretreatment (Fig.10a). Furthermore, 
the increased cell death rates induced by 50 ng/mL of TNF could also be reversed with 
BHA (Fig.10b). 
 We noted that ferritin light (Ftl) and heavy (Fth) chains were among the most 
abundant transcripts in B6.WT and B6.Sst1S macrophages. However, TNF stimulation had 
opposite effects on the Ft genes’ expression: the Fth and Ftl genes were upregulated by 
TNF in the B6.WT, but downregulated in the B6.Sst1S BMDMs. Because free intracellular 
iron has potent catalytic activity to produce damaging hydroxyl radicals from peroxide via 
Fenton reaction, we hypothesized that ROS produced in TNF-activated B6.Sst1S 
macrophages via phagocytic oxidase activity (Nox2) may lead to greater damage. We 
tested this hypothesis by adding Deferoxamine, an iron chelator, to B6.Sst1S macrophages 
along with the standard TNF treatment for 24 hours. Indeed, we observed a decrease in 
both IFNβ and Trib3 in iron-chelated samples compared to TNF alone (Fig.10c). Because 
defects in iron metabolism in macrophages lead to accumulation of lipid peroxidation 
products and eventually cell death by ferroptosis, we tested Ferrostatin, an inhibitor of lipid 
peroxidation in the Ferroptosis pathway. Ferrostatin treatment along with TNF for 24 hours 
also reduced IFNβ and Trib3 levels compared to TNF alone (Fig.10d). We confirmed the 
beneficial effects of Ferrostatin on B6.Sst1S macrophages by assessing cell survival and 
death over time in M.tb-infected cells, with and without Ferrostatin (Fig.10e). M.tb growth 
was also limited by Ferrostatin treatment in these experiments (Fig.10f). Ferrostatin 
produced the greatest improvement in infection outcome over 5 days of infection at a 
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concentration of 3µg/mL, but was also effective at a lower dose of 1µg/mL (Fig.11). These 
data demonstrate that downregulation of pathways known to prevent lipid peroxidation and 
ferroptosis (ferritin and Gpx4), may predispose B6.Sst1S macrophages to abnormal IFN-I 
pathway activation by TNF via accumulation of oxidative damage products to sublethal 
levels, which ultimately leads to poorer outcomes during M.tb infection. 
Mitochondrial dysfunction during the course of TNF stimulation in B6.Sst1S 
macrophages   
 As a potential source of iron-dependent ROS, damaged mitochondria could play a 
causative role in the aberrant B6.Sst1S response to TNF. Indeed, the pathway analysis 
suggested a defect in oxidative phosphorylation in TNF-stimulated B6.Sst1S macrophages 
(Fig.9A). Also, our previous studies demonstrated increased mitochondrial membrane 
permeability transition in M.tb-infected B6.Sst1S macrophages. Taken together, these 
observations suggested that mitochondrial dysfunction may underlie the B6.Sst1S 
phenotype.  
 We compared mitochondrial function in quiescent and TNF-stimulated B6.WT and 
B6.Sst1S macrophages using standard Seahorse Extracellular Flux Analysis. We observed 
an increase in Basal Oxygen Consumption Rates (OCR) and ATP-linked respiration (ATP 
production) and reduced reserve capacity of mitochondria after 18 h of TNF stimulation in 
both B6.WT and B6.Sst1S macrophages, but observed no significant differences in those 
parameters between strains under standard conditions (Fig. 12A). However, we did observe 
a TNF-dependent strain difference in Extracellular Acidification Rate (ECAR) after 
inhibition of oxidative phosphorylation by FCCP and Antimycin. This difference, 
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observable only in the absence of mitochondrial energy production, reflects either a greater 
TNF-induced glycolytic rate in the absence OxPhos or an impaired pH buffering capacity 
in B6.Sst1S.  
 With the intent of modeling the resource-poor environment of a granuloma in vivo, 
we modified the Seahorse experimental conditions by removing the glucose and pyruvate 
supplementation from the assay medium.  Under these conditions, B6.WT macrophages 
retained their responsiveness to TNF, but B6.Sst1S macrophages showed no increase in 
Basal OCR or ATP production with TNF (Fig. 12B). These data suggested to us that TNF 
stimulation for 18 h induced a hidden defect in mitochondrial function that became 
apparent only at low substrate levels. We also documented damaging effects of TNF 
stimulation on mitochondrial morphology using transmission electron microscopy (TEM).  
After 48 hours of TNF stimulation, we observed a morphological change of widened 
mitochondrial cristae in both B6.WT and B6.Sst1S with TNF (Fig.12C). However, 
morphological changes were more severe in B6.Sst1S mitochondria, characterized by 
matrix “void” structures with absent cristae (Fig.12C, bottom right). Potentially, the 
observed mitochondrial dysfunction could drive the aberrant TNF response of B6.Sst1S 
macrophages via mitochondrial ROS production. However, we excluded this hypothesis, 
because a mitochondria-targeted ROS scavenger MitoTempo [152] suppressed neither the 
IFNβ super-induction, nor the ISR marker expression (Fig.12D).  
 Another known mechanism linking mitochondrial damage to IFN-I and PKR 
activation is the leakage of mitochondrial RNA (mtRNA) to cytoplasm and activation of 
dsRNA sensors, including RIG-I and PKR [153]. To test this hypothesis, we stimulated 
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B6.Sst1S macrophages with TNF in the presence of Doxycycline, which is known to 
specifically inhibit mtRNA transcription. However, this treatment demonstrated no 
significant effects on either IFNβ or Trib3 induction by TNF (Fig.12E). In contrast, 
triptolide, an inhibitor of RNA polymerase II-mediated nuclear transcription [154], 
significantly reduced the Trib3 induction by TNF (Fig.12F). The triptolide effect was 
maximal when it was added at 12 - 18 h of TNF stimulation, i.e. during a critical interval 
of the aberrant IFNβ upregulation followed by the ISR escalation. Importantly, the 
triptolide treatment specifically inhibited the ISR, as it had no effect on IFNβ or 
housekeeping gene levels, thus excluding a possibility that its effect was non-specific due 
to a global transcription inhibition. The data also demonstrated that, at least initially, 
nuclear transcripts were recognized by PKR, but not other RNA sensors that, otherwise, 
would upregulate IFNβ transcription. Taken together, these data demonstrate that 
mitochondrial damage is present as a consequence of the aberrant response of the B6.Sst1S 
macrophages to TNF, rather than its cause. 
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DISCUSSION 
The role of TNF in necrotization 
 The two major advantages of the B6.Sst1S TB infection model are the chronic, 
human-like infection course, and the direct comparison between TB-resistant and 
susceptible strains of near identical genetic background. The benefits of this model and its 
relevance to human disease has been discussed in detail in previous publications [21, 25], 
but here we focus on the direct comparison of responses to TNF in B6.Sst1S and B6.WT 
macrophages. We find that TNF alone is sufficient to trigger a cascade of unresolving stress 
in B6.Sst1S that leads to increased cell death at high signal concentration, and exacerbates 
the effects of additional stressors, including infection, even at low levels. This sequence of 
stress, dysregulation, and increased cell death is not observed in B6.WT--it correlates with 
the sst1S genotype. Constant TNF stimulation is required to maintain the full effects of 
dysregulation in B6.Sst1S, and this constant stimulation model in vitro mimics the 
granuloma environment in vivo. Activated macrophages inside an established granuloma 
produce a supply of TNF for newcomer macrophages, which encounter the TNF on the 
granuloma periphery [155], and can become dysregulated before ever encountering the 
mycobacteria near the center of the granuloma (Fig. 13A). Thus, the cycle of dysregulation 
we describe likely contributes directly to granuloma necrotization in vivo. 
 It must be emphasized that while levels of TNF may differ somewhat between 
infected mice of B6.WT and B6.Sst1S lineages (as discussed further below), the strain 
differences that we demonstrate are dependent on the downstream responses to TNF rather 
than on TNF concentrations. This is clear from the differential strain responses to the same 
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concentrations of TNF, combined with the observation that removing TNF from the growth 
medium stops further signaling, indicating that in this two-dimensional monolayer system, 
the macrophages are not producing significant amounts of TNF compared to the exogenous 
concentration. A major aspect of the differential response to TNF is the lack of tolerance 
in B6.Sst1S macrophages. TNF tolerance is a phenomenon characterized by increased 
IκBα turnover and decreased phosphorylation of downstream effectors such as p65, p38 
and c-Jun [156, 157]. We observed the effects of TNF tolerance in B6.WT macrophages in 
restimulation experiments, in which a second stimulation period with TNF resulted in a 
decrease in the IFNβ response to baseline, about a 10-fold decrease from the initial 
stimulation. However, in B6.Sst1S macrophages, the response to TNF restimulation was 
only partially reduced, compared to initial stimulation, indicating a failure of the tolerance 
mechanisms. This is in contrast to the non-restimulated samples, in which removal of TNF 
after 24 hours results in a 10-fold decrease in IFNβ transcript levels by 48h in both B6.WT 
and B6.Sst1S macrophages. Although not fully elucidated, the mechanisms of tolerance 
are known to involve repression of the NFκB system [157], which may relate to the 
transcriptional dysregulation expected in the absence of the sst1 gene locus (discussed 
below). This connection may merit further study as our mechanistic understanding of the 
B6.Sst1S model progresses.  
PKR is a critical mechanism but not a therapeutic target 
 Our previous manuscript demonstrated the role of TNF and JNK in IFNβ 
superinduction in B6.Sst1S from 12 to 16 hours after stimulation [25]. As we explored the 
propagating mechanisms of this dysregulation, we confirmed that TNF and JNK remain 
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primary drivers of IFNβ at both early and late time points, but also discovered a more 
complex role for PKR. PKR is known to be a mediator of Integrated Stress Response 
activation by IFNβ in B6.Sst1S, but it was not known to induce IFNβ. In other models 
however, PKR has been shown to activate JNK, either via ASK1 [145], or via MAVS 
[158], which provides a potential route for feedback to IFNβ. Another alternative feedback 
loop involving increased NFκB activity due to ISR-mediated downregulation of IκB 
translation has also been shown [159]. However, we excluded ISR-mediated feedback as a 
primary mechanism due to the observation that global ISR inhibition by ISRIB did not 
affect IFNβ levels. Furthermore, inhibiting either JNK or PKR after 24 hours completely 
abolishes IFNβ superinduction, and there is no additive effect because inhibition of either 
results in near 100% reduction of IFNβ levels relative to baseline. This supports the 
hypothesis that PKR and JNK are mechanistically in sequence, and suggests the PKR-JNK 
connection as a mechanism for PKR feedback to IFNβ. Since a TNF blockade also 
abolishes IFNβ induction, we proposed that TNF, JNK and PKR are all in the same 
mechanistic pathway as follows: TNF and JNK (activated by proteotoxic stress via TNF-
induced ROS) induce IFNβ through NFκB and c-Jun, causing the superinduction seen at 
12 hours. High levels of IFNβ induce PKR, which when activated, reduces proteotoxic 
stress by activating the Integrated Stress response, thus becoming the primary driver of 
JNK and feeding back on IFNβ.  
 One caveat of this model is that we do not yet know the source of PKR activation. 
PKR is canonically RNA-dependent, and is often thought of as a viral response kinase, but 
no virus is present in our system. However, PKR can also be activated by endogenous 
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RNAs, including mitochondrial dsRNA and structured nuclear ssRNA [62]. 
Experimentally, we considered multiple options for PKR activators, excluding 
mitochondrial sources but demonstrating a role for nuclear RNA. TNF mRNA has been 
demonstrated as a potential activator of PKR [160], as have snoRNAs under certain 
metabolic stress states [66]. It is possible that endogenous TNF production drives PKR 
activation in B6.Sst1S, as exogenous TNF can stimulate endogenous production [161]. 
SnoRNAs may also be involved, as the mitochondrial dysfunction mimics aspects of 
metabolic stress, and the dysregulation of transcriptional control due to the loss of the sst1 
locus may contribute further to this stress. However, we have not ruled out a role for PACT, 
the protein activator of PKR which functions in an RNA-independent manner [45, 162]. 
PACT is known to activate PKR in response to a variety of cellular stresses [70], including 
ER stress [163] and oxidative stress [73, 164]. Given our observations of oxidative stress 
in the B6.Sst1S macrophages, PACT remains a potential mechanism by which PKR could 
be activated in the absence of viral RNA. While we have not yet defined a specific 
mechanism, we do have clear evidence of a TNF-induced stress that activates PKR in 
B6.Sst1S.  
 We also have evidence that PKR activity mitigates this TNF-induced stress, as 
prolonged inhibition of PKR exacerbates ISR marker induction. In the absence of active 
PKR, eIF2α can be phosphorylated via three other activators: GCN2, HRI, and PERK [28]. 
GCN2 activates the ISR in response to amino acid starvation [165], by recognizing 
uncharged tRNAs. However, it also responds to stressors such as peroxide, DNA damage 
by UVC or MMS, proteasome inhibition, or viral infection [166]. Of these stressors, only 
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peroxide is observed and may be a source of GCN2 activation in the B6.Sst1S system. HRI 
is a more likely source of ISR activation, because in addition to its response to heme 
deficiency [167], it also responds to oxidative stress [168]. Although most studied in 
erythroid lineages, HRI is expressed (and activated by LPS) in murine macrophages [169]. 
Furthermore, HRI activates NFκB signaling via HSPB8 and NOD1, while also being 
necessary for MAVS signaling, but not MyD88 or STING [170]. This is consistent with 
our observations of IFNβ induction by NFκB, but not IRF3 [25], as well as the potential 
feedback to JNK by MAVS. These connections, along with the observed oxidative stress 
in the B6.Sst1S system, make HRI a strong candidate for a secondary ISR activator 
alongside PKR in our system. Finally, PERK is a transmembrane kinase that activates the 
ISR as part of the Unfolded Protein Response (UPR) in the ER [171]. The upregulation of 
Heat Shock proteins and presence of protein aggregates in TNF-stimulated B6.Sst1S 
macrophages strongly suggest an ongoing UPR [172], and thus, PERK is likely activated 
as well. TNF therefore promotes a condition of cellular stress, to which multiple eIF2α 
kinases respond by inhibiting translation. As a consequence, the negative effects of ISR 
activation in this system of dysregulation cannot be reduced by inhibiting PKR without 
additional measures to reduce the underlying stress (Fig. 13B).  
Iron-driven ROS as a driver of Type I Interferon and Mycobacterial susceptibility 
 In addition to our study of the mechanisms downstream of our core IFNβ 
phenotype, these studies also revealed an upstream connection to the B6.Sst1S genotype. 
Upstream of IFNβ superinduction, we demonstrate a critical dysregulation of free iron-
dependent ROS, in which a failure of the antioxidant response and iron control mechanisms 
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results in ongoing stress in B6.Sst1S. An excess of free-iron leads to lipid peroxidation 
[173]. Lipid peroxides induce cell death via the ferroptosis pathway, however we do not 
observe rapid cell death in B6.Sst1S at the TNF concentrations used in our experiments. 
Rather, we observe that lipid peroxides contribute to gradual damage and dysregulation 
vial IFN-I induction. Ferrostatin is a ferroptosis inhibitor, but its mechanism is the 
inhibition of lipid peroxide formation [174]. Thus the survival benefit we observe with 
ferrostatin use in M.tb-infected B6.Sst1S macrophages is not inhibition of ferroptosis, but 
prevention of the damaging cascade of IFNβ induction by lipid peroxides. The survival of 
the mycobacteria does not appear to be negatively affected by an excess of peroxide 
products, likely due to mycobacterial superoxide dismutases, which promote 
mycobacterial survival even in highly oxidative environments [175]. Rather, we observe 
the opposite: with increased macrophage survival after ferrostatin treatment, mycobacterial 
proliferation is reduced. This indicates that, with the removal of damaging lipid peroxides, 
B6.Sst1S macrophages continue as functional phagocytes, rather than merely persisting as 
fodder for the growing infection.  
 Further upstream of lipid peroxidation, we produce similar effects by blocking iron-
dependent ROS production with an iron chelator. Deferxoamine (DFOM) is a synthetic 
iron chelator used to treat a variety of conditions in humans [176], and in our infection 
model of TNF-stimulated macrophages, we see an increase in macrophage survival and a 
decrease in mycobacterial growth with DFOM treatment. Mechanistically, we suggest that 
exogenous DFOM compensates for the excess free iron in B6.Sst1S macrophages. Ferritin 
is an endogenous iron-sequestering protein, which under normal conditions, is induced by 
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TNF, free iron, and oxidative stress, and is downregulated by c-myc [177]. In B6.Sst1S, we 
instead see a reduction of ferritin transcript with TNF, which represents a key difference 
upstream of much of the dysregulation observed in the B6.Sst1S strain.  
A mechanism to connect IFN-I dysregulation to the Sst1 gene locus 
 Ferritin is downregulated by c-myc, and higher levels of c-myc have been observed 
in TNF-stimulated B6.Sst1S, which may represent a loss of overall transcriptional 
repression. This is consistent with our understanding of the sst1 locus that is absent in our 
susceptible strain. The sst1 locus contains multiple genes, including those encoding murine 
SP110 and SP140 [21]. The human homologs to both of these genes are active in immune 
cells including macrophages [22]. Consistent with our findings, meta-analysis indicates 
that the expression of SP110 and Sp140 is up-regulated in many disorders characterized by 
increased type I IFN activity (see Table 4). Human SP140 is also an Interferon-stimulated 
gene, has been implicated in autoimmune disorders such as Multiple Sclerosis and Crohn’s 
Disease as well as intracellular infections like Listeria and Legionella, and can be reduced 
by anti-TNF therapy in responsive Crohn’s patients [178]. Importantly, SP140 contains a 
bromodomain, and has been observed to localize to H3K4me3- and H3K27me3-rich 
promoter and enhancer sites [22], likely acting as a molecular enforcer of gene suppression. 
Thus, it is not surprising that our SP140-deficient murine macrophages have a defect in 
transcription regulation upon stimulation with TNF, or that PKR is activated by a nuclear 
RNA (possibly a snoRNA, as mentioned above), which may be un-suppressed in the 
absence of SP140. While we do not yet understand the full mechanism behind the 
epigenetic dysregulation in our B6.Sst1S model, the discovery that iron chelation and 
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antioxidant response genes are involved is an important mechanistic insight into the 
connection between the loss of the sst1 gene locus and the development of oxidative stress.  
 Human SP110 is also a transcriptional regulator, that has been demonstrated to 
perform various functions depending on its isoform [23]. SP110b, which has the highest 
structural similarity to the murine Ipr1 protein encoded by the sst1 locus, has been shown 
to modulate NFκB activity, downregulating TNF production and upregulating anti-
apoptotic gene expression [179]. This is known to influence cell survival and granuloma 
progression in M.tb infection models, but it may help to explain the excess levels of IFN-I 
in TB-infected susceptible mice. Given our new understanding that constant TNF 
stimulation is required for sustained IFNβ superinduction in B6.Sst1S macrophages, the 
disinhibition of TNF production in mice lacking Ipr1/SP110b is a likely mechanism for 
providing this constant, higher level of TNF stimulation, that promotes continual IFN-I 
upregulation. Of course, in humans the exact contributions of the various isoforms of 
SP110 are more complex, as isoforms B and C both downregulate p50 dimer-driven TNF 
expression, while isoform A upregulates it [23].This suggests that multiple stimuli are 
integrated to fine-tune a transcriptional response, and further study would be needed to 
refine our understanding of these exact mechanisms.  
Relevance of mitochondrial dysfunction 
 The discovery of mitochondrial dysfunction may also tie in with the loss of SP140. 
SP140 has been linked to changes in oxidative phosphorylation (OXPHOS) [180], and in 
B6.Sst1S, we were able to observe dysfunction in our seahorse analysis under resource-
poor conditions. It is worth noting that the seahorse trace for the resource-poor conditions 
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is not interpretable in the same manner as with standard conditions. Both strains exhaust 
their energy reserves over the course of the experiment, resulting in inaccurate maximal 
and non-mitochondrial OCR, thus we only interpret the basal OCR as showing a clear 
difference before the cells’ reserves are exhausted. RNA sequencing revealed that 
oxidative phosphorylation genes are decreased with TNF in B6.Sst1S compared to B6.WT 
levels. These data are in apparent contradiction with an observed trend of increased OCR 
in TNF-treated B6.Sst1S macrophages as measured by our Seahorse analysis under 
standard conditions. An explanation for this paradox is that transcript levels of OXPHOS 
pathway components are a better measure for mitochondrial biogenesis than mitochondrial 
function. In non-stressful conditions, B6.Sst1S mitochondria appear to function equally 
well to B6.WT, and it is only in stressful situations, as in the absence of sufficient substrate, 
or after prolonged stimulation with TNF, that the reduced capacity for mitochondrial 
biogenesis results in impaired function or morphological change (Fig. 13C). Additionally, 
the morphologies we observed in B6.Sst1S after prolonged TNF stimulation are similar to 
those reported in other studies, and relate to conditions of oxidative stress [181, 182]. This 
further suggests that the mitochondrial dysfunction is due to an ineffective response to 
oxidative stress, rather than a direct consequence of SP140 loss which would be observable 
before TNF stimulation.  
 Mitochondria are also involved in multiple pathways of cell death, including 
apoptosis, pyroptosis, and necroptosis, a death pathway observed in M.tb infection [183, 
184]. Damage to the mitochondria, which may occur in B6.Sst1S macrophages via 
unbuffered ROS, could contribute to both mitochondrial dysfunction and cell death. 
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Persistent oxidative damage results in more extensive damage to mitochondrial DNA than 
to nuclear DNA, leading to loss of mitochondrial membrane potential [185]. Furthermore, 
while transient or low grade mtDNA damage typically results in mitochondrial fusion to 
compensate, loss of mtDNA repair enzymes, or damage in excess of the repair capacity of 
these enzymes, results in mitochondrial-driven cell death [186]. This mitochondrial 
damage, coupled with the B6.Sst1S-dependent defect in mitochondrial biogenesis 
discussed above, result in gross mitochondrial dysfunction and contribute to macrophage 
death in the B6.Sst1S system.  
SP140 and the B6.Sst1S model 
 Previous reports find SP140 knockouts display an increase in oxidative 
phosphorylation components [180], whereas we observed a decrease. The B6.Sst1S model 
is not directly comparable to a single gene knockout, rather it involves the loss of a gene 
locus including multiple genes, resulting in a more complex phenotype. Furthermore, the 
B6.Sst1S model is not a complete knockout, as RNA sequencing reveals extant, albeit very 
low levels of SP140 and SP110 transcript. This demonstrates what is both a great strength 
but also a significant limitation of this study: the double-edged sword of the B6.Sst1S 
model. A strength of the B6.Sst1S mice are that they provide a well-characterized model 
of M. tuberculosis infection and IFN-I dysregulation, and the combined loss of multiple 
SP100-family genes provides a unique and reliable phenotype of IFNβ dysregulation. 
However, this model, with its greater complexity and the incomplete understanding of its 
exact genetic defects, provides a challenge when comparing it to single-gene knockouts. 
We consider SP140 to be the strongest candidate for the driver of our phenotype, and a 
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recent publication by Daisy et al. demonstrates that SP140 is a critical factor that allows 
macrophages to respond appropriately to bacterial infections [187]. This exciting discovery 
explains the evolutionarily conserved role of SP140 in controlling inflammation and 
immune function. Future studies may aim to compare mechanisms of dysregulation in the 
B6.Sst1S model to the effects of specific knockouts to better analyze the mechanisms of 
epigenetic regulation that underlie the dysfunction observed in susceptible macrophages.  
 SP110, SP140 and the sst1 locus play a larger role in immunity outside of the 
context of bacterial infection. SP140 polymorphisms have also been linked to Multiple 
Sclerosis and Crohn’s disease. These SP140-related diseases display certain phenotypes 
common to our model as well, including mitochondrial dysfunction [188, 189]. Other roles 
for SP140 and the sst1 locus include functioning as a tolerance mechanism for 
inflammatory damage [190] and directing macrophage maturation [180]. Appropriately 
regulated macrophages subjected to TNF stimulation polarize to a pro-inflammatory state, 
developing internal protections in preparation for the upcoming stress of expected pathogen 
encounters. B6.Sst1S macrophages, do not display all the hallmarks of pro-inflammatory 
polarization, as they do not respond inappropriately to TNF, are more prone to oxidative 
stress, and have higher production of growth-related transcription factor c-myc. The 
underlying loss of sst1 may impair appropriate maturation in B6.Sst1S macrophages, 
leading to this anomalous state. 
 Control of macrophage polarization by SP140 would lead to a nuanced phenotype, 
in which deficiencies are only observed in certain environmental contexts. A similar gene- 
and environment-dependent dysfunction has been studied for SP110, in the context of 
61 
diabetes development in organ transplant recipients [191]. In this study, a polymorphism 
of SP110 was linked to new-onset diabetes after transplant, but not to development of 
diabetes in the general population. This suggests that the function of SP110 becomes 
critical in certain immunological contexts—in this case, pharmacological immune 
suppression after transplant—and that variation in its regulatory function results in 
pathology in such a context. This is similar to our observations of B6.Sst1S mice, in which 
the loss of sst1-encoded genes is only consequential in the context of an immunological 
challenge such as intracellular infection. This furthers our understanding of the SP110 and 
SP140 as context-dependent, but not disease-specific, immunological regulators. While 
much remains to be explored, SP110, SP140 and the sst1 locus are beginning to show 
relevance to a variety of human diseases and the field of macrophage immunology as a 
whole, and we expect the discoveries presented here will contribute to further 





 The above experiments defined the links between sst1-dependent iron 
dysregulation, oxidative stress and IFNβ superinduction leading to susceptibility to 
infection (Fig. 14). However, the scope of dysregulation in B6.Sst1S macrophages is 
broader than this direct sequence of mechanistic causes and effects. To better define the 
B6.Sst1S macrophage system, we analyzed additional aspects of macrophage function, 
including metabolism, senescence, and chromatin regulation. We also explored 
downstream consequences of dysregulation, including outcomes of prolonged infection in 
vitro, and in vivo responses to non-infectious inflammatory stimuli. The following section 
describes and interprets the results of these experiments. 
The mitochondrial dysfunction in B6.Sst1S is independent of Type 1 IFN.  
 We have demonstrated mitochondrial dysfunction under stress conditions in 
B6.Sst1S. Mitochondrial damage induces Type 1 IFN by mtDNA leakage and 
cGAS/STING activation, [76] or by mt-dsRNA leakage and activation of PKR [62]. 
cGAS/STING signals to IFNβ through IRF3, which has not been shown to play a 
significant role in the IFNβ superinduction phenotype in B6.Sst1S [25]. Therefore mtDNA 
leakage is not a major inducer of IFNβ, at least at observed time points. Mt-dsRNA, being 
more abundant and of smaller size than mtDNA, could escape into the cytosol earlier than 
mtDNA, and was expected to play a role in IFNβ superinduction. However, experiments 
using doxycycline to inhibit mitochondrial transcription showed no effect on IFNβ 
induction. Instead, triptolide, an inhibitor of nuclear transcription (RNA pol-II), did reduce 
IFNβ transcription, even when normalized to housekeeping genes 18s rRNA, GAPDH, and 
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β-actin (Figure 12, e,f, data shown normalized to GAPDH). This suggests a PKR-
activating RNA that is nuclear in origin, not mitochondrial.  
 Interaction of Mitochondrial function and IFNβ induction was also considered in 
reverse: that increased IFNβ could ultimately damage mitochondria. Possible mechanisms 
of this interaction include Rsad2-mediated mitochondrial interactions, itaconate disruption 
of ATP production, or ISR-induced imbalance between mitochondrial and nuclear proteins. 
These effects of IFNβ on the mitochondria are likely to occur in a chronic setting, and may 
contribute to the cell death seen over multiple days, as in the infection experiments. 
However, we have also observed mitochondrial dysfunction at early time points after TNF 
stimulation in B6.Sst1S, which does not appear to be dependent on IFNβ. Therefore, this 
dysfunction, seen only in B6.Sst1S and not in B6.WT, must represent a separate, B6.Sst1S-
dependent defect, in a pathway parallel to IFNβ superinduction. To reveal any effects of 
IFNβ on mitochondrial function, Seahorse Extracellular Flux Analysis was performed on 
B6.Sst1S macrophages with TNF stimulation in the presence or absence of an anti-IFNAR 
antibody to block the autocrine effects of IFNβ on the macrophages. These experiments 
were performed in supplemented media (Fig.15a,b) and unsupplemented media 
(Fig.15c,d), in order to observe effects in resource-poor conditions. No significant increase 
in OCR was observed with an IFNβ blockade, even at time points up to 36h post-TNF. 
Although not significant, a slight trend towards decreased mitochondrial respiration was 
observed in B6.Sst1S with the IFNAR blocker, suggesting some benefit of IFNβ signaling 
to mitochondrial function, rather than IFNβ-induced damage. We conclude that IFNβ 
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superinduction does not contribute to the early stage mitochondrial dysfunction observed 
in B6.Sst1S macrophages upon TNF stimulation.  
Markers of senescence, including NAD/NADH and SA-βgal, are dysregulated in 
B6.Sst1S. 
 Observing functional deficiencies in the absence of cell death suggested that 
B6.Sst1S macrophages exposed to TNF enter senescence. This possibility was explored by 
examining two markers associated with senescence: NAD+/NADH levels, and Senescence-
associated β-galactosidase (SA-βgal). SA-βgal is a classical marker for functional 
senescence, including replicative senescence, non-replicative or telomere-independent 
senescence, and a “senescence-like phenotype,” a stress-induced state of functional decline 
observed in macrophages [192, 193]. SA-βgal is a lysosomal enzyme [194], and the 
observation of SA-βgal in the cytosol indicates lysosomal compromise and functional 
decline of the cell. Lysosomal dysfunction occurs in certain disorders of aging [195], which 
suggests that age-related is the mechanism of increased cytosolic SA-βgal in replicative 
senescence. Using SA-βgal, we observed a higher basal level of senescence in B6.Sst1S, 
as well as an increased level with TNF stimulation.  
 NAD+ metabolism also plays a role in cellular senescence [196]. TNF regulates 
NAD+ metabolism in primary macrophages [197] and the THP-1 macrophage like cell line 
[198]. In these previous studies, TNF induced a rapid increase of NAD+ in pro-
inflammatory, but not anti-inflammatory macrophages, although its complex interactions 
resulted in an overall decrease in levels over time. Senescence and intracellular NAD+ 
concentrations are particularly relevant for macrophages in the context of infection with 
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M. tuberculosis. Virulent M.tb expresses the ESX-1 secretion system, which penetrates the 
phagolysosomal membrane, allowing the mycobacteria to enter the macrophage cytosol 
[199, 200]. This is in contrast to related mycobacterial strains, including the M. bovis BCG 
vaccine strain, which do not express ESX-1, and remain in the phagolysosome, and are 
significantly less virulent [201]. The observation of cytosolic SA-βgal, which is normally 
sequestered in lysosomes [194], suggests that lysosomal integrity is compromised. If this 
instability extends to the fused phagolysosome, it may result in easier exit of mycobacteria, 
even avirulent strains, into the cytosol. Alternatively, poor lysosomal integrity may prevent 
efficient phagolysosome fusion, in which case phagocytosed mycobacteria could persist 
and grow in the unfused phagosome. Additionally, NAD+ concentrations are independently 
relevant in virulent M.tb infection. Included in the mycobacterial secretion machinery is a 
virulence factor called Tuberculosis Necrotizing Toxin (TNT), which functions as an 
NAD+ glycohydrolaze [202], reducing the intracellular concentrations of NAD+ to cause 
macrophage necroptosis [203, 204]. Therefore, optimal control of mycobacterial infection 
by macrophages is likely to benefit from a TNF-induced increase in NAD+ concentrations.  
 We analyzed SA-βgal as a measure of cellular senescence, using a fluorescein 
substrate-based assay for cytoplasmic β-galactosidase activity. We observed that B6.Sst1S 
macrophages trend toward higher SA-βgal activity than B6.WT, and that this difference is 
increased with TNF stimulation for 24-48 hours. (Fig.16a). Senescence is known to 
correlate with mitochondrial dysfunction [205], which we have previously demonstrated 
in B6.Sst1S, and our findings are consistent with this correlation. We then explored the 
involvement of IFNβ and the ISR with senescence by testing the effects of the PKR 
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inhibitor c16.  We found that in B6.Sst1S, inhibiting PKR activity with C16 demonstrates 
a clear trend of reduced SA-βgal activity, as measured by a fluorometric assay (Fig.16b). 
It is not yet known whether PKR drives SA-βgal through IFNβ or through the ISR. 
However, there is evidence that IFNβ activates p53 to promote senescence (measured by 
SA-βgal) in response to oxidative stress [206]. Evidence also exists that ISR activators 
promote cellular senescence in a p53-independent manner [207]. Therefore, it is possible 
that PKR activity in B6.Sst1S promotes senescence though both pathways. 
 We next measured NAD/NADH levels in B6.Sst1S and B6.WT macrophages, 
using another fluorometric assay kit. A trend of higher baseline NAD+ or NADH levels in 
B6.Sst1S macrophages was observed, with differential responses to TNF between 
B6.Sst1S and B6.WT. This trend is most pronounced at 36h of TNF stimulation. With 
50ng/mL TNF, B6.WT macrophages increase, or maintain NAD+ and NADH levels 
compared to untreated. In contrast, in B6.Sst1S macrophages, NAD+ and NADH levels 
remain constant or decrease with TNF stimulation (Fig.16c). To determine whether the 
TNF-induced dysfunction in NAD+/NADH levels mechanistically involves IFNβ 
superinduction, we tested the effects of the PKR inhibitor C16 to interrupt the cycle of 
IFNβ superinduction and reduce both IFNβ and ISR transcript levels. In B6.Sst1S 
macrophages stimulated with 50ng/mL TNF for 36h, C16 added 6 hours before harvest 
restored the TNF-dependent increase in NAD+ and NADH levels, while having no effect 
on B6.WT macrophages (Fig.16d).   
 The TNF-dependent increase in NAD+ and NADH in B6.WT is consistent with our 
understanding of these macrophages as pro-inflammatory. However, this increase is not 
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observed in B6.Sst1S cells, which we have hypothesized as being less able to differentiate 
into pro-inflammatory macrophages. This strain difference in NAD+ and NADH appears 
to be dependent on IFNβ, or PKR-dependent induction. Little evidence exists for direct 
IFNβ modulation of NAD+ levels, but it is possible that ISR inhibition of translation 
prevents synthesis of enzymes such as IDO and PBEF that are responsible for the NAD+ 
increase [197], which might provide a mechanism for this observation. Additionally, given 
that low NAD+ concentrations can lead to necroptosis in TB infection, the inability of 
B6.Sst1S macrophages to increase NAD+ concentrations at later time points may directly 
contribute to the increased cell death observed in the M.tb infection studies.  
Assay for Transposase-Accessible chromatin sequencing (ATAC-seq) supports 
hypothesis of widespread chromatin disinhibition in B6.Sst1S 
 We have hypothesized a mechanistic link between the dysregulation observed in 
B6.Sst1S macrophages and the loss of the sst1 genetic locus, which contains homologs to 
human SP110 and SP140 [179]. It is known that SP110 is linked to tuberculosis 
susceptibility in humans, [208] and that SP140 knockouts in mice display an B6.Sst1S-like 
phenotype [187]. These SP100 family proteins are involved in DNA binding, and contain 
bromodomains (BRD) which are involved in acetylated histone recognition [209]. Based 
on the domains, SP110 and SP140 are believed to reinforce transcriptional repression, and 
their absence is predicted to facilitate chromatin changes that result in transcriptional 
activation. We explored this in B6.Sst1S macrophages using the Assay for Transposase-
Accessible Chromatin with Sequencing (ATAC-Seq) to observe the chromatin status of 
our cells.  
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 ATAC-Seq is a high-throughput sequencing technique that uses tagged, artificial 
transposable elements to sequence regions of open euchromatin. In this method, chromatin 
is isolated and incubated with transposase loaded with two “halves” of a known sequence. 
The transposase inserts these DNA fragments into the accessible regions of chromatin. The 
result is that areas of euchromatin, where DNA is more accessible, are broken into short 
fragments bounded by known sequences, allowing the fragment to be sequenced, whereas 
condensed chromatin is resistant to transposition, and will not be detected upon 
sequencing. High throughput sequencing and alignment of sequences to a genome database 
allows for a mapping of areas of open and closed chromatin across a genome. This allows 
analysis of overall chromatin regulation, and also allows an unbiased comparison of 
differences in epigenetic regulation in functional clusters of genes between B6.WT and 
B6.Sst1S. A more detailed description of the process can be found in the publication by 
Buenrostro et al, 2015 [138].  
 Using this technique, we analyzed B6.Sst1S and B6.WT macrophages, both with 
TNF treatment and without. Initial experiments indicate a trend of B6.Sst1S macrophages 
having the higher levels of open chromatin accessible to transposase activity compared to 
B6.WT macrophages (Table 14a). This suggests reduced heterochromatin in B6.Sst1S, 
and is consistent with our expectation of the transcriptional repression activity of the SP110 
and SP140 proteins. Interestingly, TNF treatment appears to have differential effects on 
the two strains. In both strains, TNF increases certain areas of euchromatin and reduces 
others, consistent with activation and deactivation of various transcriptional programs. 
However, in B6.WT, there is a slightly greater proportion of activated euchromatin sites 
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than deactivated, while in B6.Sst1S, more euchromatin peaks are decreased with TNF than 
activated (Table 14b).  
 To determine the function of these activated euchromatin sites, we performed 
functional clustering analysis using the functional clustering tool from DAVID (Database 
for Annotation, Visualization, and Integrated Discovery, Laboratory of Human 
Retrovirology and Immunoinformatics) [139, 140]. We excluded general terms such as 
“immunity” given the monocyte lineage of the samples. We found several clusters that 
correspond to our understanding of the dysfunction observed in B6.Sst1S macrophages. 
These clusters include transcription factors, cell cycle regulators, mitochondrial function, 
and lysosomal function, which were epigenetically de-repressed in B6.Sst1S compared to 
B6.WT at baseline, as well as cell junction and cytokine activity, which were relatively 
repressed in B6.Sst1S compared to B6.WT with TNF (Table 14c). Additionally, the “cell 
cycle” cluster is highly enriched in untreated B6.Sst1S macrophages, and to a lesser degree 
after TNF treatment. This observation, along with the reduction of euchromatin with TNF 
in B6.Sst1S, may indicate a dysregulated maturation process in response to TNF. In such 
a case, a less mature population of B6.Sst1S macrophages is unable to quickly exit the cell 
cycle and reduce general transcription and cell growth functions when encountering TNF. 
Thus, while mature B6.WT macrophages respond to TNF by transitioning to a pro-
inflammatory phenotype, the B6.Sst1S macrophages retain some immature functions, 
responding less efficiently to TNF, and thus unable to adequately remove mycobacteria 
[210].  
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Cell survival during infection with moderate MOI of M. tuberculosis is improved by 
TNF, but reduced by PKR inhibition and early IFNAR blockade 
 The goal of exploring the underlying mechanisms of dysregulation was to gain 
insights into TB infection. We established an in vitro infection model with virulent M.tb to 
explore applications of our mechanistic understanding to potential therapeutic strategies. 
In these experiments, we treated macrophages with TNF or left untreated for 24h, before 
infecting them with M.tb at low MOI. We used MOI less than 1 to reduce artifacts of rapid 
cell death due to overwhelming bacterial growth. This strategy also allows us to more 
definitively explore the effects of intrinsic cell mechanisms that lead to dysfunction and 
death, as most of the cells in culture will not encounter the pathogen. Uninfected cells 
encounter paracrine effects from the few infected cells, and the overall culture responds to 
dysregulation without being destroyed by the infection. This setup allows us to mimic the 
in vivo granuloma environment, in which a small number of mycobacteria ignite a large 
inflammatory process.  
 Across several experiments, we observed the effects of known dysregulation on the 
survival and death rates of B6.Sst1S macrophages. TNF stimulation (10ng/mL) induces 
increased rates of cell death over time, and increases the lethality of infection in B6.Sst1S 
at very low MOI (Fig.4), or at higher MOI over shorter periods (Fig.2g). However, 
additional experiments late in infection (day 9) suggest that TNF pre-treatment plays a 
protective role in managing TB infection. We observed the effects of TNF and IFNβ-
pathway inhibitors on cell survival at increasing MOI. In the absence of infection, we 
confirmed that prolonged treatment of B6.Sst1S macrophages with TNF is detrimental to 
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survival, but in infection at MOI of 0.1, 0.3 and 1, TNF pretreatment conferred survival 
benefits (Fig. 17a). Although this appears to contrast with our previous studies, the 
experimental conditions are different, with higher MOI and longer-term infection course. 
Further experimentation will be needed to dissect the exact mechanisms of these 
conflicting effects of TNF. However, this suggests that TNF plays a complex role, neither 
purely detrimental nor beneficial, and this is consistent with studies showing that TNF 
blockers interfere with innate immunity in the context of TB infection [211].  
 We next attempted to manipulate elements downstream of TNF-induced signaling 
to improve survival without compromising immune function. We blocked the ISR and 
IFNβ superinduction by inhibiting PKR activity with c16, and observed a significant 
reduction in cell survival (Fig. 17b). This supported our previous conclusions that PKR 
plays a necessary stress-response role in the B6.Sst1S system, and that long-term inhibition 
of PKR actually increases ISR activity. We concluded that the stressors that induced cell 
death with infection were upstream of IFNβ and PKR, and could not be resolved by 
downstream blockade of these pathways. Similarly, blocking IFNβ signaling through 
IFNAR after infection resulted in no survival benefit (Fig. 17c, left). IFNAR blockade 
initiated before infection even resulted in a trend of decreased survival (Fig. 17c, right). 
This suggests that some IFNβ may prepare the macrophages to encountering the 
mycobacteria, though a prolonged excess of IFNβ is detrimental. 
B6.Sst1S mice display differential responses to LPS, a non-infectious inflammatory 
stimulus.  
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 The above experiments were conducted using a stimulus of M. tuberculosis 
infection, TNF, or both, to mimic the cytokine environment of a tuberculous granuloma. 
This was our primary focus due to the initial characterization of the B6.Sst1S mice as a 
model of immune dysfunction in the context of TB or other intracellular infections [21]. 
However, we now understand that the underlying defect in transcriptional regulation in 
B6.Sst1S leads to a suboptimal stress response. This broader mechanism implies that the 
B6.Sst1S system may be an effective model for studying unrelated inflammatory 
conditions. As proof of this concept, we tested the tolerance of the B6.Sst1S mice to a non-
infectious septic shock, using a stimulus of intraperitoneal LPS. We injected a single dose 
of 2.5, 5, 10, or 20 mg/kg LPS intraperitoneally in a small cohort of B6.Sst1S, B6.WT, and 
C3HeB/FeJ Mice. C3HeB/FeJ mice were used because they contain the same sst1 gene 
variant as the B6.Sst1S mice. The C3HeB/FeJ strain is the source of the B6.Sst1S gene 
variant that was cross-bred onto the B6.WT strain to create the B6.Sst1S mice, and is also 
sometimes used as a TB susceptibility model. We monitored the mice three times daily for 
5 days after the initial injection, and recorded weights and health scores. At all doses, we 
observed that the B6.Sst1S mice displayed worse outcomes compared to B6.WT mice, with 
worse health scores and greater and more prolonged weight loss after induction of shock 
(Fig. 18). Given the sst1-dependent differences observed between B6.WT and B6.Sst1S 
mice, we can confidently say that the sst1 locus regulates immune function in multiple 
contexts, and that the B6.Sst1S mouse model is likely to be useful for studying 
inflammatory disorders beyond intracellular infection. C3HeB/FeJ mice displayed a 
moderate response, worse than B6.WT but less severe than B6.Sst1S, except at the highest 
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dose, suggesting that other factors are involved that compensate for the loss of function in 
the sst1 gene locus. Therefore, they may not be an adequate model for further study of the 
sst1 locus, and may not be as appropriate as B6.Sst1S for studying other inflammatory 




Relevance of findings to Tuberculosis Disease 
The in vitro infection model of in vivo granulomas 
 A major strength of our studies is the ability to model a chronic infection with M. 
tuberculosis without the need to infect live animals for weeks. While in vivo infection 
provides critical information at the organism level, the variability between individual hosts, 
combined with the time required to complete a single experiment, make in vivo mechanistic 
studies both challenging and inefficient for biochemical analysis. Our in vitro infection of 
isolated macrophages in monolayer was ideal for our mechanistic dissection of the 
pathways involved in chronic dysregulation and eventual cell death with infection. 
However, we need to consider the strengths and weaknesses of the in vitro system in order 
to apply our understanding of this model to future studies of human disease.  
 Our in vitro model isolates and matures BMDMs, generating a monolayer of 
primary differentiated macrophages. This has several benefits. First, we can study cell-
intrinsic effects and exclude unwanted external stimuli. We used this isolation to determine 
that the sst1 gene locus plays a role in iron regulation and ROS buffering, with direct 
downstream consequences on IFNβ induction, stress responses, and mitochondrial 
function, and that this specifically (but not exclusively) occurs in BM-derived 
macrophages, which are the main infected cells in a chronic TB granuloma [14]. Second, 
by isolating a specific cytokine signal, without T-cell interactions or additional cytokines 
from other immune cells, we were able to determine that TNF is sufficient to activate a 
cycle of dysregulation in B6.Sst1S macrophages. Third, the use of primary macrophages 
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provides a better comparison of in vivo function than transformed cell lines. An alternative 
system that is often used for cellular and biochemical characterization of macrophage 
responses is a monocyte cell line like THP-1. THP-1 cells are human monocyte-like 
immortalized cells from a case of acute monocyte leukemia, and function similarly to 
primary monocytes for many applications [212]. However, this cell line differs from 
primary monocytes in aspects such as LPS response [213], TNF secretion, and M1/M2 
polarization [214], and it continuously self-renews.  Given the phenotypic differences 
caused by even a single gene locus deletion in the case of sst1, we determined that our 
primary cell model was preferable to a cell line derivative for studying M.tb infection. 
 Despite the strengths of this in vitro primary cell model, future experiments could 
optimize this system to better approximate a three-dimensional granuloma. Some studies 
have already developed three dimensional models using primary cells in a collagen matrix 
[215], and future studies may use these models or improve on them to reap several key 
benefits. It would allow study of the cell-cell interactions between macrophages that might 
not exist in a monolayer culture. Cell-cell interactions in macrophages have been 
implicated in processes such as attenuation of TNF secretion upon contact with apoptotic 
cells [216], viral transmission [217], and formation of multinucleated giant cells [218], 
although there is some controversy about this third point, as giant cells have also been 
described as developing from mitotic, non-dividing macrophages [219]. Closer cell 
clustering would also amplify the effect of paracrine signals, such as IFNβ, which could 
amplify the effects of superinduction. A three dimensional model might allow for a study 
of hypoxic conditions in the granuloma center, which has been shown to impact both 
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macrophage and bacterial processes, and might affect the oxidative stress in the B6.Sst1S 
system [220]. Studying infection in a three-dimensional structure might reveal dynamics 
of macrophages clustering around a bacterial locus, more so than the indiscriminate 
infection of a monolayer. The two-dimensional infection model can only partially mimic 
the clustering of macrophages around a small bacterial focus by using low MOI. In the 
monolayer system, relatively few macrophages are infected, mimicking the centers of the 
granuloma, and surrounding uninfected cells experience paracrine effects. However, a 
three-dimensional model would allow for the study of more complex interactions between 
bacteria and macrophages, progressive macrophage death, and transmission of pathology 
and infection to outer layers of macrophages. As a bonus, developing a three-dimensional 
model could allow for integration of multiple cell types, including CD4 T-cells, to generate 
a more complex and more accurate model for study.  
 An additional limitation to these studies is the widespread use of small molecule 
inhibitors for the mechanistic studies. We attempted to minimize the errors in interpretation 
caused by off-target effects by comparing effects of multiple inhibitors for a single target 
(as with PKR), using structural or isotype controls (as with PKR inhibitor C16, or anti-
IFNAR antibody), or using previously validated small molecule inhibitors (as with JNK 
inhibitor sp600125). However, we cannot completely exclude the possibility of off-target 
effects in our mechanistic studies, which may be a confounding factor in interpreting our 
results. Future studies may corroborate the results described here with genetic knock-down 
of key elements, in order to independently verify these results. However, we have shown 
that the effects of some pathway elements, such as PKR, are dependent on timing. To 
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properly understand the changing effects of these elements over time, it was necessary to 
use small molecule inhibitors, which can be administered at precise time points, instead of 
genetic knockdowns, which would affect the entire course of the experiment. Inducible 
knockdowns present a possible solution, although the timing of these manipulations would 
be dependent on protein degradation rates, and would still be less precise than small 
molecule inhibitors.  
Applications of the B6.Sst1S model mechanisms to human disease 
 In the B6.Sst1S model system, specific similarities to human disease are useful to 
determine which aspects of the model are likely to translate. As previously discussed, the 
sst1 gene locus encodes the homologs to human SP110 and SP140 [21]. Polymorphisms 
of SP110 have been associated in humans with tuberculosis susceptibility [208], and SP140 
polymorphisms in select populations have been associated with susceptibility to other 
intracellular bacteria including Listeria and Legionella [209]. Human populations are 
heterogenous, and the prevalence of susceptibility-linked variants in the general population 
is not yet known. However, as individualized medicine becomes increasingly 
commonplace, it is possible that interventions developed specifically in B6.Sst1S mice 
could be directly applied to SP110 and SP140-variant humans with TB as well.  
The B6.Sst1S macrophage model provides critical information about downstream factors 
that contribute to TB susceptibility. It is known that excess Type 1 Interferon production 
correlates with tuberculosis virulence [221, 222], and B6.Sst1S mice have been already 
used to study downstream consequences of IFN-I superinduction [29]. Considering the 
importance of IFNβ and its consequences, the upstream drivers of IFNβ dysregulation 
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should now be studied for their impact on human disease. PKR has been studied in human 
neurodegenerative disease such as Alzheimer’s [223], and has been previously studied in 
mouse models for Tuberculosis [224], but has not been subject to a detailed mechanistic 
analysis or been studied extensively in human non-viral infections. Most previous studies 
used genetic knockouts to study the absence of PKR, but such models may develop 
compensatory mechanisms, while any intervention in human disease would involve 
manipulating a system that includes and relies on PKR. In our experiments, mice with 
functional PKR depend on its function for the mitigation of stress conditions, and that long-
term PKR inhibition is detrimental. Therefore, in future experiments, PKR inhibition 
should be tested in combination with upstream interventions that reduce the underlying 
stress. This way, the negative effects of PKR activity might be reduced without causing 
major complications or overwhelming stress.  
 Additionally, the role of PKR in resolving stress, and its positive effect on outcomes 
of TB infection, are dependent on its activation by nuclear RNA in the B6.Sst1S system. 
Other publications have suggested that PKR is dispensable or detrimental to TB infection 
outcomes [225, 226]. These studies show no effect of PKR function or regulation on 
outcomes in C57Bl/6J mice, and some benefit of a PKR regulatory domain-knockout in 
129S1/SvImJ mice. These observations are actually consistent with our studies, in which 
PKR inhibition has no effect on IFNβ induction in B6.WT (C57Bl/6J) macrophages. We 
only observed PKR activation in B6.Sst1S macrophages under TNF stimulation, while in 
B6.WT macrophages, we observe no induction of ISR markers, and conclude that PKR is 
not activated. Therefore, knockout of a functional or regulatory domain of PKR is not 
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expected to have an impact in B6.WT macrophages. However, in the context of an 
activating stressor, such as the transcriptional dysregulation that we observe in B6.Sst1S, 
PKR plays a role in the stress response, and improves infection outcomes.  
 The studies described herein have provided insights into the underlying stressors 
that induce PKR and influence susceptibility to M.tb infection.  Firstly, transcriptional 
dysregulation appears to play an important role as a source of cellular stress. In the 
B6.Sst1S model, loss of the SP110 and SP140 homologs promoted a baseline increase in 
global transcription, which was associated with an overreaction to TNF stimulation. 
Nuclear RNA was indicated to activate PKR, which amplified IFNβ induction and initiated 
the Integrated Stress Response. The hypothesis of transcriptionally dysregulated nuclear 
RNA activating PKR was supported by chromatin studies that revealed extensive regions 
of de-repression in B6.Sst1S mice. However, it is not yet clear whether the euchromatin 
regions correspond to regions of active transcription, nor whether the chromatin 
dysregulation is a direct consequence of reduced SP110 and SP140 levels or whether 
additional mechanisms are at play. Additional experiments using the B6.Sst1S model or 
the SP140 knockout mouse may clarify this connection in the future. Still, we hypothesize 
that excess RNA molecules produced in B6.Sst1S might activate PKR, either by forming 
double stranded structures themselves or overwhelming the post-translational processing 
machinery to exit the nucleus as incorrectly spliced or 5’ triphosphate RNAs. Under 
baseline conditions, these RNAs are mostly ignored, due to the low level of PKR protein 
in unstressed cells. TNF then triggers a cascade which induces the production of PKR in 
addition to creating oxidative stress, and the higher levels of PKR allow increased 
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sensitivity to the existing dysregulated RNAs. This occurs even though TNF attenuates the 
transcriptional dysregulation, possibly due to persistence of the overproduced RNA. In 
humans, SP110 or Sp140 polymorphisms might exhibit similar effects of transcriptional 
deregulation and increased PKR sensitivity, although other conditions such as 
mitochondrial disease or even chronic viral infection, such as HIV, might play a role in 
provoking a disproportionate PKR response in the context of TB infection. Similarly, in 
other disorders, a variety of RNA sources could play an equivalent role in activating PKR 
and sensitizing the system to stress. 
 We have also demonstrated the role of oxidative stress as a driver of pathology in 
TB-susceptible macrophages. In the B6.Sst1S system, a dearth of ferritin and the resulting 
inability to sequester free iron results in lipid peroxidation and a cascade of cellular 
dysfunction. Lipid peroxide activation of JNK leads to induction of IFNβ, which in turn 
reduces the macrophages’ effectiveness in combatting a TB infection. Developing 
therapeutics to limit overall ROS is challenging because the respiratory burst is a major 
mechanism by which macrophages kill phagocytosed mycobacteria [227], although 
targeting mycobacterial oxidative and antioxidant processes is a viable strategy, using 
antibiotics such as isoniazid [228]. Any host-directed therapies developed to strengthen the 
macrophage against TB should focus not on reducing ROS, but on improving macrophage 
resistance to oxidative damage. It has been shown that classically activated, pro-
inflammatory macrophages tolerate higher levels of oxidative stress than undifferentiated 
or alternatively activated macrophages [229], and we have indications that B6.Sst1S 
macrophages are not appropriately differentiated to a pro-inflammatory state. Further 
81 
studies on the activation state of these macrophages may provide additional clues about 
their lack of resistance to oxidative stress, and how these findings may translate to 
therapeutic strategies in humans involving steering granuloma macrophages toward an 
appropriate activation state. 
 Oxidative stress is associated with clinical TB in humans. Dietary studies have 
demonstrated an inverse correlation between antioxidant vitamins and higher risk of TB 
infection [230], and have shown that low levels of antioxidant compounds observed in 
early infection will increase with antibiotic treatment and disease resolution [231, 232]. 
This protection by antioxidants is consistent across multiple models [233] and is thus likely 
to be a reliable property of TB infection. Furthermore the lower levels of dietary 
antioxidants correlate with increased malondialdehyde, a lipid peroxidation product [234], 
the same oxidative process we demonstrated to cause dysregulation or ferroptosis in the 
B6.Sst1S system. Another study linked ferroptosis to M.tb-induced granuloma 
necrotization [235]. Our study expands this understanding by describing the mechanisms 
by which lipid peroxidation, the underlying driver of ferroptosis, drives gradual 
macrophage dysfunction and eventual cell death. Future studies could examine lipid 
peroxidation inhibitors such as Ferrostatin-1 as therapeutic strategies in vivo and in 
translational studies. 
 One element of human tuberculosis which is difficult to account for in an animal 
model is the long history of co-evolution between humans and M. tuberculosis. TB is an 
exclusive human pathogen with no environmental reservoir, and has existed in the human 
population for at least 10,000 years, and likely much longer [236]. In this time, the 
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pathogen has adapted to survive and spread in human hosts, and humans may have begun 
evolving immune strategies in return. M.tb benefits from infecting an immunocompetent 
human host, then either driving the host’s slow decline or persisting until the host’s health 
declines from external factors such as age. TB can exist in a granuloma, evading the host’s 
immune response, until eventually reactivating when immunity is weakened. Once 
reactivated, it spreads to new hosts as subclinical disease before driving pathology 
significant enough to kill the original host. Rapid host death reduces the opportunities to 
spread to new hosts, which does not benefit M.tb. Therefore, one might expect TB infection 
to induce some host-protective effects to prevent rapid host death, and the systemic 
increase in Type 1 Interferons may contribute to some antiviral protection. Little evidence 
exists to support this though, despite a reasonable volume of literature on TB co-infection 
with other pathogens [237]. Marginally better studied, and perhaps much more important, 
are factors that signal for M.tb to transition between the latent phase and the active, 
transmittable phase. Transition into latency has been modeled using systems of progressive 
hypoxia [238], or hypoxia and nutrient starvation [239], suggesting M.tb enters latency in 
response to the hypoxic and resource-poor environment of a granuloma compared to the 
relatively oxidative environment of the alveoli. Reactivation can be achieved by reversing 
these conditions in vitro. In animal models, reactivation is often induced by means of 
immunodeficiency, either with co-infection with immunodeficiency viruses like SIV [240] 
or by blockade of cytokines such as TNF [241]. These studies suggest that reactivation can 
occur in response to granuloma compromise or waning host immunity. However, 
mycobacteria also produce molecules that drive reactivation, called Resuscitation 
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promoting factors [242, 243], suggesting that exit from the latent phase is not purely a 
reactive process. This interplay between latency and reactivation is therefore a major aspect 
of host-pathogen interaction, which complicates model studies and requires further 
investigation.  
Implications for Type I Interferon as a central mechanism of immunity 
Type I IFN responds to a variety of stressors, both infectious and non-infectious 
 Type I IFN is a canonical antiviral response mechanism, which is induced by 
exogenous DNA or dsRNA in the cytoplasm, and which limits viral replication through the 
activation of effector ISGs (Interferon-stimulated genes). However, IFNβ can also be 
induced in response to other stressors and infections, as we demonstrate in B6.Sst1S 
macrophages. Rather than constraining our conception of IFNβ to an anti-viral context, we 
should instead understand IFNβ’s role as a more general mechanism for dealing with 
cellular stress. PKR contributes to the antiviral activity of IFNβ, responding to viral RNA 
to induce IFNβ [244], and becoming more abundant and sensitive as IFNβ is further 
induced. PKR also has its own antiviral activity, in the form of translation inhibition via 
the ISR. However, PKR is not purely a viral response kinase, as it can be activated by a 
variety of stimuli, including endogenous nuclear or mitochondrial RNAs, or proteotoxic 
stress via PACT. It may even function as a secondary mechanism of IFNβ induction by 
TNF [45, 62, 65]. Thus, PKR and IFNβ respond to a variety of stress states besides viral 
infection, including activating signals, mitochondrial damage, transcriptional 
dysregulation, and metabolic stress [66].  
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IFNβ responds to TNF stimulation in both healthy cells and in the dysregulated B6.Sst1S 
system. TNF is primarily induced by bacterial products, such as LPS, or in an autocrine 
fashion through NFκB [245]. Macrophages both produce and respond to TNF, thus an area 
with a high concentration of activated macrophages, such as a granuloma, will contain high 
concentrations of TNF. Alone, TNF-stimulated NFκB elements p50/RelA and IRF1 induce 
relatively low levels of IFNβ. However, these transcription factors initiate the aggregation 
of the enhanceosome to induce much higher levels of IFNβ when other transcription factors 
become involved. Thus, low-level IFNβ induction by TNF may be an anticipatory 
mechanism to reduce the reaction time of macrophages to additional stresses that could be 
encountered.  
 We have also shown that oxidative stress can play a role in inducing Type I 
Interferon. ROS induced by TNF signaling, mitochondrial activity, or the respiratory burst, 
causes peroxidation of lipids. At high concentrations, lipid peroxides cause cell death via 
ferroptosis, but at lower concentrations, they activate JNK, which induces IFNβ via c-Jun. 
While IFNβ induces iNOS and increases ROS in activated macrophages, in certain settings 
it also has an antioxidant effect, and is used for this purpose to treat Multiple Sclerosis 
[246]. Balanced or spatially separated oxidative and antioxidant responses to IFNβ might 
limit oxidative damage to phagocytosed pathogens while protecting the central functions 
of the macrophage, although to our knowledge this hypothesis has not been confirmed in 
the literature. Nevertheless, IFNβ is clearly involved in oxidative stress, a common element 
to many immune pathologies. We conclude that IFNβ is a mediator of the immune response 
to a much wider variety of insults than viral infection alone.  
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Type I IFNs and oxidative stress in non-infectious inflammatory conditions 
 Having established IFNβ as a response to non-infectious stress, we can examine its 
role in other human pathologies. As a major inflammatory mediator, IFNβ drives pathology 
in chronic degenerative or autoimmune disorders such as Systemic Lupus Erythematosus 
(SLE), celiac disease, and Parkinson’s. SLE is characterized by an increased level of IFNβ 
and ISG signatures in affected patients [247, 248]. As with our TB model, increased PKR 
expression and activity have been associated with T-cell dysfunction in SLE, a major 
feature of the disease [249, 250]. Increased oxidative stress has also been linked with SLE 
[251], and considering the mechanistic connection we have demonstrated between these 
elements in the pathogenesis of TB, it seems likely that a similar cascade of dysfunction 
may be involved in the pathogenesis of SLE as well.  
 Celiac disease is characterized by intestinal gluten intolerance due to abnormal 
response by CD4+ T cells  and dysregulation of endogenous Type 1 Interferons [252, 253]. 
New onset celiac disease has reportedly been triggered by exogenous Type 1 Interferon 
therapy for hepatitis C [254]. Taken together, these observations suggest that excess IFN-
I is a primary driver of Celiac disease, rather than a consequence. Furthermore, oxidative 
stress generated by triggering compounds in a patient’s diet may contribute to the 
pathogenesis of Celiac disease [255]. Anti-TNF therapies improve pathology in a subset of 
patients with celiac disease that is refractory to other treatments [256]. This disease process 
parallels the dysregulation observed in the B6.Sst1S macrophage model. In both cases, an 
overabundance of IFN-I or a propensity to superinduce IFN-I, reacts with an oxidative 
stress to cause inappropriate inflammatory activation and damage. The mechanisms are not 
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identical, but given the similar players, mechanistic insights from the B6.Sst1S model may 
be useful in the future study of Celiac disease.  
 Type I IFN is also studied extensively in the context of Parkinson’s Disease (PD). 
Reduction of IFN-I signaling is neuroprotective in murine models of PD [257], and IFNβ 
activity has been linked to PD-like neurodegeneration induced by Rotenone, which inhibits 
Complex I of the electron transport chain in mitochondria [258].  Human samples from PD 
patients exhibit increased levels of both Type I IFN [259] and phosphorylated PKR [260]. 
Increased TNF signaling is associated with an increased risk of developing Parkinson’s 
[261], and oxidative stress from various sources, including mitochondrial damage, plays a 
role in this disease [262]. Thus, the study of Parkinson’s disease may also benefit from 
mechanistic discoveries gleaned from the B6.Sst1S model. These three diseases are by no 
means an exhaustive list of the non-infectious pathologies involving oxidative stress and 
excess Type I IFN in humans; they are intended only to illustrate the broad scope of 





 In this dissertation we discussed several cellular mechanisms surrounding the 
induction and effects of Type 1 Interferon in the context of a model for susceptibility to 
Tuberculosis. We described the B6.Sst1S model of Type 1 Interferon superinduction and 
subsequent susceptibility to infection with M. tuberculosis. We discussed the transcription 
factors involved in the IFN-I enhanceosome, and described how each of the major 
contributors to IFNβ induction responds to various stimuli from pathogens or cellular stress 
and damage. We focused on the RNA-dependent Protein Kinase as part of a positive 
feedback loop that promotes increasing induction of IFNβ, and which drives the Integrated 
Stress Response to help the macrophage cope with the initial insult. We delved into the 
specific activators of PKR, which range from viral infection to transcriptional 
dysregulation, mitochondrial damage and proteotoxic stress, and ultimately settled on 
transcriptional dysregulation as the most likely contributor in our model. Using the 
B6.Sst1S model, we experimentally delineated a mechanism by which TNF-induced 
oxidative stress, in the context of transcriptional dysregulation, sets off a cascade of IFNβ 
superinduction and mitochondrial damage that ultimately weakens the macrophage and 
decreases its ability to survive and fight infection with M.tb. We also used an inhibitor of 
lipid peroxidation to interrupt this process, resolving IFNβ dysregulation and rescuing 
antimicrobial function. We explored aspects of dysregulated metabolic function and 
cellular senescence, analyzed chromatin organization to reveal transcriptional 
dysregulation, and tested the mouse model’s response to a non-infectious, inflammatory 
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stimulus. We concluded by discussing the relevance of our findings to Tuberculosis and to 
Type 1 Interferons in other human diseases.  
 The implications of these findings and literature review are intended to further the 
study of tuberculosis immunology, and to improve understanding of innate immunity as a 
whole. Future studies may build on these mechanistic studies to develop host-directed 
therapies for human TB centered around controlling oxidative stress in granuloma 
macrophages. The evaluation of these mechanisms should prove useful in any future study 
that uses the B6.Sst1S model, either to study tuberculosis or as a model of excess IFN-I 
production. Finally, future work in adjacent fields of immunology and autoimmune disease 
may benefit from this improved understanding of IFNβ induction mechanisms under 
oxidative stress, and may develop applications for a well-characterized B6.Sst1S model of 
IFN-I dysregulation in new contexts. Overall this work has contributed to the 
knowledgebase of the immunology field, and that they represent another step forward in 




APPENDIX 1: FIGURES 
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Figure 1. Introductory models 
A. Schematic of typical granuloma organization: 
1. Outer layer of lymphocytes, primarily CD4+ T cells, but also including CD8+ 
 T cells and B cells. IFNγ produced here. 
2. Fibrotic layer formed by epithelioid macrophages 
3. Inner layer of macrophages, including some infected cells. TNF produced here. 
4. Innermost core of necrotic debris and free mycobacteria.  
5. Healthy lung tissue surrounding the granuloma. 
B. Simplified schematic of the pathways leading to the transcription factors involved in the 
IFNβ enhanceosome. *PKR plays a role in multiple pathways in this schematic, asterisk 
present to emphasize the connections between pathways. 
C. Overview of oxidative processes leading to Ferroptosis. Free iron catalyzes hydroxyl 
radical formation from hydrogen peroxide. Hydroxyl radicals react with fatty acids to 
produce lipid peroxyl radicals, which further react with additional fatty acids to produce 
additional radicals and lipid peroxides. If lipid peroxides are not converted to lipid alcohols 






Figure 2. The Response to TB infection is a chronic and varied process involving the 
formation of progressive necrotic lesions.  
Histomorphologic phenotypes affiliated with chronic M.tb infection in B6.Sst1S mouse 
strain. 
A. Subgross image displaying heterogeneity of lesion size and type, including variably 
sized granulomatous bronchopneumonia (^) and a discrete caseating granuloma (*). Higher 
magnifications of the aforementioned lesions are depicted in Figures C and D respectively.  
B. Subgross image of necrotizing pneumonia phenotype. Although similar in 
histomorphologic features, there is diverse variability in lesion size. Higher magnification 
of this phenotype is outlined in Figure E.   
C. Focal granulomatous bronchopneumonia. Alveolar spaces adjacent to multiple 
bronchioles are flooded with macrophages, admixed with multifocal lymphoid aggregates.  
D. Caseating granuloma phenotype. Well demarcated, with a peripheral rim of collagen, 
radiating aggregate of macrophages, and central core of necrotic cellular debris. Inset. 
Immunohistochemistry (IHC). Abundant Mycobacterium tuberculosis antigen in the 
caseating granuloma, predominating within macrophages, but also within the necrotic core.  
E. Necrotizing pneumonia phenotype. Discrete focus of lytic necrosis consisting of necrotic 
cellular debris, fibrin, and degenerative neutrophils. Inset. Acid Fast Bacteria (AFB)-Ziehl-
Neelsen Stain,  abundant AFB within necrotic focus. Scale bars = 350 micrometers. A-C, 
100x; Inset B, 630x; Inset C, 200x.  
F. Cell death in B6.Sst1S and B6.WT BMDMs stimulated with increasing concentrations 
of TNF for 24h. Cytotoxicity was measured by PI/Hoechst staining and automated 
microscopy. Representative experiment of 3 repeats. Error bars indicate standard deviation 
of technical replicates, significance values determined by paired t-test of technical 
replicates.  
G. B6.Sst1S macrophages were pretreated with TNFα (10 ng/mL) for 16 h or left untreated, 
then infected with M.tb at MOI 1. The cells were harvested 3 days post-infection and 
analyzed for cell survival and death. The M.tb load was observed using a qPCR-based 
method, normalized to a BCG spike for internal control. Error bars indicate standard 
deviation of technical replicates, significance values determined by 2-way ANOVA with 







Figure 3. Mechanisms of cell death Increased cell death of B6.Sst1S BMDMs after 48 h 









Figure 4: Cell death of BMDMs during chronic infection with virulent M.tb in vitro 
is mediated by TNF in sst1-dependent manner. The B6.Sst1S and B6.WT BMDMs were 
infected with M.tb H37Rv (MOI 0.1) in vitro. 10 ng/mL TNF was added to experimental 
group samples 24h before infection, and was added again immediately following media 
changes, which occurred every 2 days. At harvest, infected cells were stained with “Live-
or-Dye” fixable viability stain (Biotium), fixed in 4% PFA, co-stained with Hoechst, and 
counted using the Nexelcom Celigo fluorescent plate reader microscope. A: Representative 
time-course; relative cell death calculated using total dead cells divided by total cells 
counted, normalized to B6.WT untreated. Error bars indicate standard deviation of 
technical replicates. No statistical significance determined in cell death rates. B: Repeat 
experiments at Day 8 post-infection. Relative cell count determined as total cells minus 
dead cells, normalized to B6.Sst1S uninfected controls. Error indicate standard deviation 









Figure 5. TNF induces and sustains a severe and prolonged IFNβ response in 
combination with JNK and PKR.  
A. B6.Sst1S and B6.WT BMDMs were stimulated with 10ng/mL TNF for 24h, after which 
media was changed and cells were either re-stimulated with TNF or left unstimulated. 
Samples were harvested and qRT-PCR was performed after the first 24h of stimulation, or 
48h after the original stimulation. One representative experiment shown out of four 
performed, error bars represent SD of technical replicates. Significance values in table 1 
(two-way ANOVA).  
B. B6.Sst1S BMDMs were treated as in (A), except upon media change at 24h, were also 
treated with anti-IFNAR antibody or isotype control. Fold induction between antibody and 
control were compared to determine percent inhibition. Significance determined by 
comparison to isotype control (one-way ANOVA).  
C. B6.Sst1S BMDMs were stimulated with 10ng/mL TNF for 24 or 36h or left 
unstimulated, and were treated with a TNF-blocking antibody 4, 12, or 24h before harvest, 
as indicated, or left untreated as a control. qRT-PCR was performed on sample RNA to 
determine IFNβ induction, compared to untreated samples (dotted line).  Significance 
determined by RM-ANOVA with multiple comparisons.  
D. B6.Sst1S BMDMs were treated with TNF and analyzed by qRT-PCR as in (C), but 
inhibitors were added 6h before harvest to determine the dependence of IFN on pathways 
downstream of TNF stimulation. Inhibitors include anti-IFNAR antibody, JNK inhibitor 
sp600125, Integrated Stress Response inhibitor (ISRIB), and the PKR inhibitors 2-
aminopurine and C16. C16 compared to its non-inhibitory structural control. Significance 
determined by ratio-paired T tests.  
E. Representative timecourse of c16’s effect on IFN induction from 12 to 30h of TNF 
treatment in B6.Sst1S. C16 added 6h before each harvest point. Fold induction of TNF + 
c16 compared to TNF only and untreated to determine % inhibition by c16. Error bars 
represent SD of technical replicates.  
F. Left: Example Western blot of Thr 446 Phospho- and total PKR with actin loading 
control in B6.Sst1S. PKR is both induced and activated in B6.Sst1S BMDMs by TNF alone 
at 24 h. Right: Quantification of three Western blots confirming PKR activation. 
Densitometry by ImageJ software. Significance by RM-ANOVA with multiple 





Figure 6: JNK inhibitor reduces levels of IFNβ transcript induced by TNF. B6.Sst1S 
BMDMs were stimulated with TNF for 34 hours, or left unstimulated. JNK inhibitor was 
added to samples 18, 22, 26, or 30 hours after TNF, and RNA samples were collected at 
34 h. The IFNβ mRNA was measured using qRT-PCR. Fold induction is normalized to 
untreated controls. Single experiment shown; error bars represent standard deviation of 










Figure 7. The Integrated Stress Response is activated in B6.Sst1S, via PKR, in 
response to overarching, TNF-induced cellular stress.  
A. B6.Sst1S and B6.WT BMDMs were stimulated with 10ng/mL TNF for 24h, after which 
media was changed and cells were either re-stimulated with TNF or left unstimulated. 
Samples were harvested and qRT-PCR was performed after the first 24h of stimulation, or 
48h after the original stimulation. See Figure 2A for experimental layout. One 
representative experiment shown of four performed, error bars represent SD of technical 
replicates. Significance data in table 1.  
B. B6.Sst1S BMDMs were treated as in (A), except upon media change at 24h, were also 
treated with anti-IFNAR antibody or isotype control. Fold induction between antibody and 
control were compared to determine percent inhibition.  
C. B6.Sst1S BMDMs were stimulated with 10ng/mL TNF for 24 or 36h, or left untreated, 
with a TNF-blocking antibody added 12h before harvest. qRT-PCR was performed on 
sample RNA to determine Trib3 induction, compared to untreated samples (dotted line). 
Significance determined by paired T-test.  
D. B6.Sst1S BMDMs were stimulated with TNF for 24h, then media was changed and 
BMDMs were restimulated with new TNF, or TNF with 2uM C16, for an additional 24h 
before harvest. qRT-PCR was performed for Trib3 and Chac1 to determine relative fold 
induction. One representative experiment shown, of two performed. Significance by paired 
T-test.  
E. B6.Sst1S BMDMs were stimulated as in (F), with the addition of samples restimulated 
at 24h with TNF and ISRIB (10uM) and TNF with ISRIB and c16 in combination. qRT-
PCR was performed as in (F). Single experiment shown, error bars represent standard 
deviation of technical replicates.  
F. B6.Sst1S BMDMs were stimulated for 24h with TNF or left untreated, with inhibitors 
ISRIB or C16 added 6h before harvest and analysis by qRT-PCR. Significance determined 
by paired and ratio-paired T test for C16 and ISRIB, respectively.  
G. B6.Sst1S BMDMs were treated with TNF, harvested and analyzed as in (D), but c16 








Figure 8: C16 reduces IFNβ at 48h. B6.Sst1S BMDMs were treated with TNF, harvested 
and analyzed as in Figure 6F, but qRT-PCR was performed for IFNβ. Significance by 








Figure 9. Gene Expression Analysis 
A.  Gene expression profiling of B6.Sst1S and B6.WT BMDMs stimulated with TNF (10 
ng/ml) for 12 hours 
Top panel - Gene regulatory network analysis. The network represents a 
subnetwork of Sp110/Sp140 genes from the mice macrophage gene regulatory 
network. Only first neighbors of Sp110/Sp140 genes were selected. Green nodes 
represent transcription factors, blue nodes denote their potential targets. The mouse 
macrophage gene regulatory network was inferred using GENIE3 algorithm based 
on external gene expression data for mice macrophages derived from Gene 
Expression Omnibus (GEO).  
Bottom panel - Gene expression profiles for a list of genes. The heatmap was 
generated using RNA-seq expression profiles of B6.Sst1S and B6.WT 
macrophages at 12 hours of TNF treatment. For heatmap generation, FPKM values 
were scaled using Z-scores for each tested gene. 
B. Analysis of genes related to oxidative stress. The heatmap was generated using FPKM 
values of genes related to response to oxidative stress (gene ontology category GO: 





Figure 10: The B6.Sst1S phenotype and susceptibility to M.tb is dependent upon iron-
induced oxidative stress. 
A. BHA pretreatment for 24h before and throughout 24h of TNF stimulation in B6.Sst1S
BMDMs reduces IFN and Trib3 RNA induction, relative to untreated controls.
Significance by ratio-paired T-test.
B. B6.Sst1S and B6.WT were treated for 48h with 50ng/mL TNF, TNF plus BHA, or left
untreated, and analyzed by PI staining and fluorescent cell counting to determine cell death
rates. Single representative experiment shown, of three repeat experiments. Error bars
represent standard deviation of technical replicates.
C. B6.Sst1S BMDMs were treated with TNF or TNF plus deferoxamine for 24h, and
compared to untreated controls by qRT-PCR for IFNβ and Trib3. Single representative
experiment shown, additional experimental data in tables 7 and 8. Error bars represent
standard deviation of technical replicates.
D. B6.Sst1S BMDMs were treated with TNF or TNF plus Ferrostatin for 24h, and
compared to untreated controls by qRT-PCR for IFNβ and Trib3. Single representative
experiment shown, additional experimental data in tables 9 and 10. Error bars represent
standard deviation of technical replicates.
E. B6.Sst1S macrophages were pretreated with TNFα (10 ng/mL) for 8 h and subsequently
treated with TNFα in combination with Ferrostatin 1 (3 μM) for 16 h. The cells were
infected with M.tb at MOI 0.5 and harvested at 1, 3 and 5 days post-infection and analyzed
for cell survival and death. Error bars indicate standard deviation of technical replicates,
significance values determined by 2-way ANOVA with multiple comparisons.
F. B6.Sst1S macrophages were treated as in (E) and harvested at 1, 3 and 5 days post-
infection.  The M.tb load was determined using a qPCR-based method, normalized to a
BCG spike for internal control. Error bars indicate standard deviation of technical
replicates, significance values determined by 2-way ANOVA with multiple comparisons.
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Figure 11: M.tb infection with 1μM Ferrostatin. B6.Sst1S cells were pretreated with 
TNF (10 ng/mL) for 8 h and subsequently treated with TNF in combination with Ferrostatin 
1 (1 μM) for 16h. The cells were harvested 1, 3, and 5 days post-infection and analyzed for 
cell survival and death. The M.tb load was observed using a qPCR-based method, 
normalized to a BCG spike for internal control. Error bars indicate standard deviation of 









Figure 12: B6.Sst1S mitochondria are differentially affected by TNF stimulation, but 
do not drive the B6.Sst1S phenotype. 
A. B6.WT and B6.Sst1S BMDMs were isolated and treated with 10ng/mL TNF or left 
untreated. 18 hours after stimulation, cell media was changed to Agilent Seahorse medium, 
supplemented with glucose, pyruvate and L-glutamine, and then assayed using the Agilent 
Seahorse Extracellular Flux Analyzer, using standard protocols for Oxygen Consumption 
Rate analysis. Left: Example traces for OCR and ECAR analysis. Right: Graphical analysis 
of Basal OCR, Maximal OCR, and ATP production for each strain. N=5 experiments, error 
bars represent standard deviation. Statistical analysis by RM-One way ANOVA with 
multiple comparisons. *p < 0.05, ** p < 0.01. 
B. B6.WT and B6.Sst1S BMDMs were treated as in (A), but Seahorse analysis was 
performed in Agilent Seahorse medium without supplemental glucose, pyruvate or L-
glutamine. Top: Representative OCR trace. Bottom: representative values for Basal OCR, 
Maximal OCR and ATP. Error bars represent standard deviation of technical replicates. 
Trace data for n=3 total experiments provided in table 11.  
C. B6.WT and Sst1-S BMDMs were treated with 10ng/mL TNF for 48h, or left untreated. 
Cells were then collected and fixed for TEM imaging. 50000x TEM images (1000nm scale 
bar provided) reveals mitochondrial ultrastructure. Notable morphological changes 
observed include widened mitochondrial cristae in TNF-treated BMDMs, regardless of 
strain, and large mitochondrial matrix “voids” in B6.Sst1S mitochondria. Both 
morphological phenomena indicated by green arrows. Additional quantification of images 
provided in table 12.  
D. B6.Sst1S macrophages were treated with 10ng/mL TNF or TNF plus MitoTempo ROS 
scavenger. qRT-PCR analysis was conducted for IFNβ and Trib3 and normalized to 
untreated controls. No significance observed for IFNβ or Trib3 by ratio-paired T tests.  
E. B6.Sst1S macrophages were treated with 10ng/mL TNF or TNF plus Doxycycline. qRT-
PCR analysis was conducted for IFNβ and Trib3 and normalized to untreated controls. No 
significance observed for IFNβ or Trib3 by ratio-paired T tests.  
F. B6.Sst1S macrophages were treated with 10ng/mL TNF for 18 or 24h, or left untreated. 
Triptolide was added to indicated samples either 12 or 18 hours after TNF. qRT-PCR 
analysis was conducted for Trib3 and normalized to untreated controls. Single experiment 
shown. Error bars represent standard deviation of technical replicates. Error bars and 











Figure 13. Models for Discussion.  
A. A granuloma structure, with hypothetical cross section, showing relative density of 
macrophages clustered around central necrotic region. Granuloma macrophages 
produce TNF, establishing a gradient of increasing TNF concentrations toward the 
areas of highest macrophage concentration. As macrophages migrate from 
peripheral blood into the granuloma structure, they encounter TNF before 
encountering mycobacteria in the center of the granuloma.  
B. Schematic of long-term PKR inactivation. Top: PKR is activated in response to a 
TNF-induced cellular stress. PKR initiates the ISR to relieve the activating stress. 
While PKR is active, other eIF2α kinases contribute minimally to ISR activation. 
Bottom: when PKR is inhibited for long periods under TNF stimulation, the 
activating stress is not reduced, and eventually activates other eIF2α kinases which 
drive the ISR in PKR’s absence. 
C. Schematic of mitochondrial function. Under high glucose conditions, TNF induces 
increased ATP production in the mitochondria of both B6.WT and B6.Sst1S 
macrophages. Under low glucose conditions, mitochondrial biogenesis is necessary 
for appropriate increase in ATP production in response to TNF. B6.WT, but not 
B6.Sst1S macrophages, increase mitochondrial biogenesis with TNF, and are thus 










Figure 14. A mechanistic overview of the dysregulation in B6.Sst1S macrophages.  
Transcriptional dysregulation in B6.Sst1S macrophages results in low ferritin levels and 
high free iron. TNF, in the presence of free iron, induces the production of lipid 
peroxides, which activate JNK and induce IFNβ. IFNβ induces PKR, which is activated 
by nuclear RNA. PKR creates a positive feedback loop with JNK to induce IFNβ, and 
also drives the Integrated Stress Response, resulting in cell death and TB susceptibility. 
Additionally, TNF induces mitochondrial dysfunction in B6.Sst1S macrophages, possibly 








Figure 15. IFNβ does not induce mitochondrial damage and dysfunction in B6.Sst1S 
A. B6.WT and B6.Sst1S BMDMs were isolated and treated with 10ng/mL TNF or left 
untreated, and administered anti-Interferon alpha receptor antibody (α-IFNAR) or 
left untreated as indicated. 18 hours after stimulation, cell media was changed to 
Agilent Seahorse medium, supplemented with glucose, pyruvate and L-glutamine, 
and then assayed using the Agilent Seahorse Extracellular Flux Analyzer, using 
standard protocols for Oxygen Consumption Rate analysis. Graphical analysis of 
Basal OCR, Maximal OCR, and ATP production for each strain. No significance 
was observed between samples treated with α-IFNAR and those left untreated, 
regardless of strain or TNF treatment. Error bars represent standard deviation. 
Statistical analysis by RM-One way ANOVA with multiple comparisons. 
B. B6.WT and B6.Sst1S BMDMs were isolated and treated as above, except that 
media was changed and assay was performed after 36 hours. Graphical analysis of 
Basal OCR, Maximal OCR, and ATP production for each strain. No significance 
was observed between samples treated with α-IFNAR and those left untreated, 
regardless of strain or TNF treatment. Error bars represent standard deviation. 
Statistical analysis by RM-One way ANOVA with multiple comparisons. 
C. B6.WT and B6.Sst1S BMDMs were isolated and treated as in (A), except that 
media was changed at 18h to Agilent Seahorse medium without supplemental 
glucose, pyruvate or L-glutamine. Assay was started within 30 minutes of media 
change. Left: Graphical analysis of Basal OCR for each strain, as Maximal OCR 
and ATP production were deemed uninterpretable due to declining rates of 
respiration in unsupplemented media over time. No significance was observed 
between samples treated with α-IFNAR and those left untreated, regardless of strain 
or TNF treatment. Right: Example trace for OCR analysis. Error bars represent 
standard deviation. Statistical analysis by RM-One way ANOVA with multiple 
comparisons. 
D. B6.WT and B6.Sst1S BMDMs were isolated and treated as in (C), except that 
media was changed and assay was performed after 36 hours. Left: Graphical 
analysis of Basal OCR for each strain. No significance was observed between 
samples treated with α-IFNAR and those left untreated, regardless of strain or TNF 
treatment. Right: Example trace for OCR analysis. Error bars represent standard 








Figure 16. Senescence-associated metabolic signatures, including NAD/NADH and 
SA-βgal are upregulated in B6.Sst1S. 
A. B6.WT and B6.Sst1S macrophages were treated with 30ng/mL TNFα or left 
untreated for up to 48 hours, after which cells were fixed and analyzed for 
Senescence-associated β-galactosidase activity by fluorescein di-β-D-
galactopyranoside according to the protocol given by the MarkerGeneTM 
Fluorescent Cellular Senescence Microtiterplate Assay Kit. Fluorescence readouts 
were normalized to cell count. A comparison of SA-β-gal activity in TNF-treated 
or untreated macrophages reveals that B6.Sst1S macrophages are significantly 
more prone to developing a senescence phenotype than B6.WT under normal 
conditions as well as TNFα-stressed conditions (p < 0.05 by Welch two sample t-
test, data summed from 18, 36, and 48h of treatment; 48h only pictured here). 
B. B6.WT and B6.Sst1S macrophages were treated with 50ng/mL TNF or left 
untreated for 24 or 36 hours , after which cells were analyzed for NAD+ and NADH 
concentrations, using the EnzyFluo NAD/NADH Assay Kit from BioAssay 
Systems, following the protocol and calculations according to the manufacturer’s 
directions for a 96-well assay. Fluorescence readouts were normalized to B6.WT 
untreated samples. Observed differences did not reach statistical significance, but 
a trend was observed of overall higher NAD+ and NADH levels in untreated 
B6.Sst1S, which declined with 36h of TNF treatment, while B6.WT levels were 
overall increased by TNF. 
C. B6.WT and B6.Sst1S macrophages were treated as in (B), with the addition of an 
experimental group treated with TNF for 36h and C16 (2µM) for 6 hours before 
harvest. Fluorescence readouts were normalized to untreated samples for each 
strain At 36h, we observed a characteristic increase in B6.WT NAD+ and NADH 
levels with TNF, with no increase observed in B6.Sst1S. Addition of PKR inhibitor 
c16 appears to rescue this increase in B6.Sst1S, while having no effect on B6.WT.  
One representative experiment shown of three performed. Error bars represent 
standard deviation of technical replicates. Statistical significance by One-way 
ANOVA with multiple comparisons.  










Figure 17. Survival rates of B6.Sst1S Macrophages infected with M.tb are improved 
with TNF treatment but worsened with PKR inhibition and early IFNβ blockade 
A. B6.Sst1S macrophages were pretreated with TNF (10 ng/mL) for 24 h or left 
untreated, then infected with M.tb at increasing MOI, as indicated, or left 
uninfected. The cells were harvested 9 days post-infection, with media changes 
every 2 days, and analyzed for cell survival. Cell counts were normalized to 
untreated, uninfected samples. Representative experiment shown. Error bars 
indicate standard deviation of technical replicates. Significance by One-way 
ANOVA with multiple comparisons. *p < 0.05, **p < 0.01, ****p < 0.0001.  
B. B6.Sst1S macrophages were treated with TNF and infected with MOI 0.3 as in (A), 
with PKR inhibitor c16 or nonfunctional structural control added after infection. 
Cell counts were normalized to untreated, uninfected sample. Representative 
experiment shown. Error bars indicate standard deviation of technical replicates. 
Significance by One-way ANOVA with multiple comparisons. *p < 0.05 
C. B6.Sst1S macrophages were treated with TNF and infected with MOI 0.3 as in (A), 
with anti-IFNAR antibody added either 4h before or 2h after infection. Cell counts 
were normalized to untreated, uninfected sample. Single representative experiment 
shown. Error bars indicate standard deviation of technical replicates. Statistical 
significance was not reached, but a trend was observed of a differential effect on 








Figure 18. B6.Sst1S mice display greater susceptibility to LPS-induced shock than 
either parental strain.  
B6.WT, B6.Sst1S, and C3HeB/FeJ mice were injected intraperitoneally with LPS in PBS 
at a dose of 2.5, 5, 10 or 20 mg/kg, and observed for a total of 5 days. Each day, individual 
mice were monitored multiple times throughout the day, and were graded on a 0-9 “health 
score” scale, receiving 0-3 points in each category of respiration, posture, and activity, with 
higher scores indicating more severe symptoms. Mice were humanely euthanized if total 
scores reached 9 for more than one observation in a day. Average scores of each cohort are 
plotted against the number of hours after the LPS injection. Error bars represent standard 
deviation of scores for each cohort at each time point. Significance determined by two-way 
ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.  
† N= 5 mice per cohort, at all time points except 20 mg/kg LPS, B6.Sst1S at 24h post 
injection. In this group, two mice were euthanized before the 24h monitoring due to severe 
symptoms overnight. All remaining mice in the B6.Sst1S and B6.WT groups at 20 mg/kg 
were humanely euthanized between 24 and 48h due to severe symptoms, and due to this, 
statistical analysis was not possible at this dosage.  
  
119 






  IFN Rsad2 iNOS IL1Ra Trib3 Chac1 
1 vs 2 **** **** **** **** **** **** 
1 vs 3 ns *** **** ns ns ns 
1 vs 5 ns *** **** ** ns ns 
2 vs 4 **** **** **** ** ** **** 
2 vs 6 **** **** **** **** **** **** 
3 vs 4 ns **** **** **** **** * 
3 vs 5 ns ns ns *** ns ns 
4 vs 6 ns **** **** **** **** ns 
5 vs 6 ns ns ns **** * ns 
Table 1: Significance values for comparisons in Figure 5A and 7A. Samples numerically 
labeled according to diagram in Figure 5A. Significance values by Two-way ANOVA. *p < 0.05, 
** p < 0.01, *** p < 0.001, **** p < 0.0001. 
Table 1 
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Gene Set Enrichment Analysis 
Table 2. Gene set enrichment analysis results for the top enriched gene sets from the KEGG, 
MSigDB Hallmark, Reactome databases when comparing B6.Sst1S vs B6.WT BMDMs 
stimulated with TNF for 12 h. Output includes gene set names and FDR corrected p-values. 








Table 3. The functional profiling and transcription factor binding sites analysis (TFBs) was 








Table 4. The table shows the identified list of transcription factors associated with 










Table 5. Master regulator analysis was performed using Virtual Inference of Protein Activity 
by Enriched Regulon Analysis (VIPER) algorithm, the mice macrophage gene regulatory 
network and log2 transformed FPKM values of genes from gene ontology category GO: 
0006979. The table shows the identified list of transcription factors associated with 


















Table 7: Sst1S BMDMs treated with Deferoxamine as described in Figure 10C, and harvested 
for qRT-PCR analysis for IFNβ. Values represent fold change in respective RNA compared to 
untreated control. Standard deviations and p-values for individual experiment were 












Table 8: Sst1S BMDMs treated with Deferoxamine as described in Figure 10C, and harvested 
for qRT-PCR analysis for Trib3. Values represent fold change in respective RNA compared to 
untreated control. Standard deviations and p-values for individual experiment were 












Table 9: Sst1S BMDMs treated with Ferrostatin as described in Figure 10D, and harvested for 
qRT-PCR analysis for IFNβ. Values represent fold change in respective RNA compared to 
untreated control. Standard deviations and p-values for individual experiment were 












Table 10: Sst1S BMDMs treated with Ferrostatin as described in Figure 10D, and harvested 
for qRT-PCR analysis for Trib3. Values represent fold change in respective RNA compared to 
untreated control. Standard deviations and p-values for individual experiment were 










































































































































































































































































































































































































Trib3 GCAAAGCGGCTGATGTCTG AGAGTCGTGGAATGGGTATCTG 























Table 14. Assay for Transposase-Accessible chromatin sequencing (ATAC-seq) 
suggests increased euchromatin in B6.Sst1S 
A. B6.WT and B6.Sst1S macrophages were treated with 10ng/mL TNF or left 
untreated for 24h, then harvested for analysis by ATAC-seq. Sequencing and 
analysis were performed, and euchromatin peaks were compared between strains 
under each treatment condition. In untreated B6.WT and B6.Sst1S macrophages, 
72 peaks were identified in promoter regions that had an increased transposition 
rate of at least 1.5x greater in B6.WT over B6.Sst1S, while 909 euchromatin peaks 
were identified in promoters increased by at least 1.5x in B6.Sst1S over B6.WT. In 
TNF treated samples, 130 peaks were increased in B6.WT over B6.Sst1S, while 
334 were increased in B6.Sst1S over B6.WT. 
B. B6.WT and B6.Sst1S samples from (A) were compared between TNF treated and 
untreated within each strain. In B6.WT, 78 promoter region peaks were identified 
to be increased by >1.5x with TNF, while 47 were increased in untreated samples 
compared to TNF treated samples.  In B6.Sst1S, 95 peaks were increased with TNF 
treatment, while 149 were increased in untreated samples relative to TNF-treated 
samples 
C. Euchromatin peaks from B6.WT and B6.Sst1S macrophages were submitted to the 
DAVID database for functional clustering for each strain and treatment group. 
Clusters were organized by Enrichment score, a measure of significance of each 
functional cluster. It is the negative log of the average p-value of the members of 
the cluster, calculated by number of members in each cluster and fold increase. 
Thus, a higher score indicates greater significance. Enrichment score > 2 is 
equivalent to p value < 0.01. Clusters with enrichment score >2 were recorded in 
this table, except “Cell cycle, Cyclins” in (p = 0.019) which was included as 
comparison to “Cell Cycle, Mitosis” with a higher score in untreated B6.Sst1S. 
B6.WT untreated samples did not display any clusters of enrichment score greater 
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